<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Nadarevic, T - 2022 | Cochrane Library</title> <meta content="Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Nadarevic, T - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014798.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease - Nadarevic, T - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014798.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014798.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease" name="citation_title"/> <meta content="Tin Nadarevic" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Agostino Colli" name="citation_author"/> <meta content="Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico" name="citation_author_institution"/> <meta content="colliagostino@gmail.com" name="citation_author_email"/> <meta content="Vanja Giljaca" name="citation_author"/> <meta content="Heart of England NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mirella Fraquelli" name="citation_author"/> <meta content="Fondazione IRCCS Ca´ Granda - Ospedale Maggiore Policlinico" name="citation_author_institution"/> <meta content="Giovanni Casazza" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Cristina Manzotti" name="citation_author"/> <meta content="Fondazione IRCCS Ca´ Granda - Ospedale Maggiore Policlinico" name="citation_author_institution"/> <meta content="Davor Štimac" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Damir Miletic" name="citation_author"/> <meta content="Clinical Hospital Centre Rijeka" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD014798.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014798.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014798.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014798.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Carcinoma, Hepatocellular [complications, diagnostic imaging]; Cross-Sectional Studies; *Liver Neoplasms [complications, diagnostic imaging]; Magnetic Resonance Imaging; Sensitivity and Specificity; Ultrasonography" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014798.pub2&amp;doi=10.1002/14651858.CD014798.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014798\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014798\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014798.pub2",title:"Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease",firstPublishedDate:"May 6, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014798.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014798.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014798.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014798.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014798.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014798.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014798.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014798.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014798.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014798.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3511 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014798.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-sec-0064"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/appendices#CD014798-sec-0079"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/table_n/CD014798StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/table_n/CD014798StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0004">Tin Nadarevic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Agostino Colli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0006">Vanja Giljaca</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0007">Mirella Fraquelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0008">Giovanni Casazza</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0009">Cristina Manzotti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0010">Davor Štimac</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information#CD014798-cr-0011">Damir Miletic</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information/en#CD014798-sec-0084">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014798.pub2">https://doi.org/10.1002/14651858.CD014798.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014798-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014798-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014798-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014798-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014798-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD014798-abs-0004">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014798-abs-0001" lang="en"> <section id="CD014798-sec-0001"> <h3 class="title" id="CD014798-sec-0001">Background</h3> <p>Hepatocellular carcinoma occurs mostly in people with chronic liver disease and ranks sixth in terms of global incidence of cancer, and third in terms of cancer deaths. In clinical practice, magnetic resonance imaging (MRI) is used as a second‐line diagnostic imaging modality to confirm the presence of focal liver lesions suspected as hepatocellular carcinoma on prior diagnostic test such as abdominal ultrasound or alpha‐fetoprotein, or both, either in surveillance programmes or in clinical settings. According to current guidelines, a single contrast‐enhanced imaging study (computed tomography (CT) or MRI) showing typical hallmarks of hepatocellular carcinoma in people with cirrhosis is considered valid to diagnose hepatocellular carcinoma. The detection of hepatocellular carcinoma amenable to surgical resection could improve the prognosis. However, a significant number of hepatocellular carcinomas do not show typical hallmarks on imaging modalities, and hepatocellular carcinoma may, therefore, be missed. There is no clear evidence of the benefit of surveillance programmes in terms of overall survival: the conflicting results can be a consequence of inaccurate detection, ineffective treatment, or both. Assessing the diagnostic accuracy of MRI may clarify whether the absence of benefit could be related to underdiagnosis. Furthermore, an assessment of the accuracy of MRI in people with chronic liver disease who are not included in surveillance programmes is needed for either ruling out or diagnosing hepatocellular carcinoma. </p> </section> <section id="CD014798-sec-0002"> <h3 class="title" id="CD014798-sec-0002">Objectives</h3> <p>Primary: to assess the diagnostic accuracy of MRI for the diagnosis of hepatocellular carcinoma of any size and at any stage in adults with chronic liver disease. </p> <p>Secondary: to assess the diagnostic accuracy of MRI for the diagnosis of resectable hepatocellular carcinoma in adults with chronic liver disease, and to identify potential sources of heterogeneity in the results. </p> </section> <section id="CD014798-sec-0003"> <h3 class="title" id="CD014798-sec-0003">Search methods</h3> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Hepato‐Biliary Group Diagnostic Test of Accuracy Studies Register, the Cochrane Library, MEDLINE, Embase, and three other databases to 9 November 2021. We manually searched articles retrieved, contacted experts, handsearched abstract books from meetings held during the last 10 years, and searched for literature in OpenGrey (9 November 2021). Further information was requested by e‐mails, but no additional information was provided. No data was obtained through correspondence with investigators. We applied no language or document‐type restrictions. </p> </section> <section id="CD014798-sec-0004"> <h3 class="title" id="CD014798-sec-0004">Selection criteria</h3> <p>Studies assessing the diagnostic accuracy of MRI for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease, with cross‐sectional designs, using one of the acceptable reference standards, such as pathology of the explanted liver and histology of resected or biopsied focal liver lesion with at least a six‐month follow‐up. </p> </section> <section id="CD014798-sec-0005"> <h3 class="title" id="CD014798-sec-0005">Data collection and analysis</h3> <p>At least two review authors independently screened studies, extracted data, and assessed the risk of bias and applicability concerns, using the QUADAS‐2 checklist. We presented the results of sensitivity and specificity, using paired forest plots, and we tabulated the results. We used a hierarchical meta‐analysis model where appropriate. We presented uncertainty of the accuracy estimates using 95% confidence intervals (CIs). We double‐checked all data extractions and analyses. </p> </section> <section id="CD014798-sec-0006"> <h3 class="title" id="CD014798-sec-0006">Main results</h3> <p>We included 34 studies, with 4841 participants. We judged all studies to be at high risk of bias in at least one domain because most studies used different reference standards, often inappropriate to exclude the presence of the target condition, and the time interval between the index test and the reference standard was rarely defined. Regarding applicability, we judged 15% (5/34) of studies to be at low concern and 85% (29/34) of studies to be at high concern mostly owing to characteristics of the participants, most of whom were on waiting lists for orthotopic liver transplantation, and due to pathology of the explanted liver being the only reference standard. </p> <p>MRI for hepatocellular carcinoma of any size and stage: sensitivity 84.4% (95% CI 80.1% to 87.9%) and specificity 93.8% (95% CI 90.1% to 96.1%) (34 studies, 4841 participants; low‐certainty evidence). </p> <p>MRI for resectable hepatocellular carcinoma: sensitivity 84.3% (95% CI 77.6% to 89.3%) and specificity 92.9% (95% CI 88.3% to 95.9%) (16 studies, 2150 participants; low‐certainty evidence). </p> <p>The observed heterogeneity in the results remains mostly unexplained. The sensitivity analyses, which included only studies with clearly prespecified positivity criteria and only studies in which the reference standard results were interpreted without knowledge of the results of the index test, showed no variation in the results. </p> </section> <section id="CD014798-sec-0007"> <h3 class="title" id="CD014798-sec-0007">Authors' conclusions</h3> <p>We found that using MRI as a second‐line imaging modality to diagnose hepatocellular carcinoma of any size and stage, 16% of people with hepatocellular carcinoma would be missed, and 6% of people without hepatocellular carcinoma would be unnecessarily treated. For resectable hepatocellular carcinoma, we found that 16% of people with resectable hepatocellular carcinoma would improperly not be resected, while 7% of people without hepatocellular carcinoma would undergo inappropriate surgery. The uncertainty resulting from the high risk of bias in the included studies and concerns regarding their applicability limit our ability to confidently draw conclusions based on our results. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014798-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014798-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014798-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014798-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014798-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014798-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD014798-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014798-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD014798-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014798-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014798-abs-0002" lang="en"> <h3>How accurate are magnetic resonance imaging (MRI) scans for detecting liver cancer?</h3> <p><b>Key messages</b> </p> <p>In people with chronic liver disease, magnetic resonance imaging (MRI: cross‐sectional scans inside the body) probably misses liver cancer in 16% of people, who would not receive timely or appropriate treatment, and incorrectly finds liver cancer in 6% of people, who would receive unnecessary treatment. </p> <p>MRI probably misses liver cancer in 16% of people with liver cancer who could have surgery to remove part of their liver, and incorrectly finds liver cancer in 7% of people who undergo inappropriate surgery. </p> <p>The studies were at high risk of bias and too different from each other to allow us to draw firm conclusions based on the evidence. </p> <p><b>Why is it important to diagnose liver cancer accurately?</b> </p> <p>Liver cancer, or 'hepatocellular carcinoma', occurs mostly in people with chronic liver disease, regardless of the cause. It is the sixth most common cancer in the world and the third most common cause of deaths due to cancer. It is difficult to diagnose because early symptoms are similar to those of liver disease. People with blood test or ultrasound results that suggest liver cancer may go on to have further tests, such as scans that produce images of the liver, or biopsy where a small piece of the liver is removed and examined. If liver cancer is detected early, people may be treated with surgery to remove part of the liver (called a liver resection) or with a liver transplant. If the liver cancer is more advanced, they may need chemotherapy. If liver cancer is missed at the diagnostic test, people will not receive appropriate treatment. However, incorrectly diagnosing liver cancer when it is not present means that people may undergo unnecessary testing or treatment. </p> <p><b>What is magnetic resonance imaging (MRI) and how might it diagnose liver cancer?</b> </p> <p>MRI produces images that show a cross‐section or 'slice' of the bones, blood vessels, and tissues inside the body. The images are a series of signal intensities that are directed and combined by a computer. MRI scans can detect the presence of abnormalities in the liver that might be cancer. Current guidelines recommend using either MRI or another type of imaging, computed tomography, or a combination to confirm the presence of liver cancer in people who might have liver cancer. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if MRI is accurate enough to diagnose liver cancer in adults with chronic liver disease. We were interested first, in liver cancers of any size and stage and second, in liver cancers that were suitable for resection. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that assessed the accuracy of MRI scans compared to the best available tests to confirm liver cancer in adults with chronic liver disease. The best available tests are examination of the liver, or part of the liver under a microscope. </p> <p><b>What did we find?</b> </p> <p>We found 34 studies assessing 4841 people.</p> <p>Around 560 of 1000 (56%) adults with chronic liver disease have confirmed liver cancer. Of these 1000 people, MRI may: </p> <p>‐ correctly detect liver cancer in 473 people;</p> <p>‐ miss liver cancer in 87 people;</p> <p>‐ incorrectly detect liver cancer in 27 cancer‐free people;</p> <p>‐ correctly detect no liver cancer in 413 people.</p> <p>Based on the studies, around 560 of 1000 (56%) adults with chronic liver disease have confirmed resectable liver cancer. Of these 1000 people, MRI may: </p> <p>‐ correctly detect resectable liver cancer in 472 people;</p> <p>‐ miss resectable liver cancer in 88 people;</p> <p>‐ incorrectly detect resectable liver cancer in 31 people;</p> <p>‐ correctly detect no resectable liver cancer in 409 people.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is limited because the studies used different methods to select study participants and used different definitions for the presence of liver disease. This means MRI scans could be more or less accurate than suggested by our analyses of the evidence. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 9 November 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014798-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014798-sec-0073"></div> <h3 class="title" id="CD014798-sec-0074">Implications for practice</h3> <section id="CD014798-sec-0074"> <p>In the clinical pathway for the diagnosis of hepatocellular carcinoma (HCC) in people with chronic liver disease, magnetic resonance imaging (MRI), as an alternative to computed tomography (CT), is currently the second step after ultrasound and alpha‐fetoprotein, or the combination of the two, and its main role is to confirm the presence of the disease. As an ideal diagnostic test, MRI should ensure a low proportion of false‐negative results because people with undetected HCC cannot receive proper treatment. Meanwhile, people with false‐positive results are exposed to unnecessary further diagnostic workup and possible invasive treatment. We meta‐analysed the results of 34 studies and estimated a sensitivity of about 84% and a specificity of about 94% suggesting that 16% of people with HCC would be missed, and 6% of people would receive unnecessary additional tests or even treatments. Considering the 16 studies that assessed the MRI diagnostic accuracy for resectable HCC, we obtained similar estimates than for any size any stage HCC; 16% of people with HCC would be incorrectly classified as without any HCC, while 7% of people without carcinoma will undergo inappropriate further testing or surgery. For people on a waiting list for orthotopic liver transplantation for an indication not related to a HCC, the consequences of false‐negative results of preoperative MRI are not completely known and might be less severe: studies report no significant difference in terms of overall survival and tumour recurrence compared to people with previously diagnosed HCCs (<a href="./references#CD014798-bbs2-0127" title="CastilloE , PelletierS , KumerS , AbouljoudM , DivineG , MoonkaD .Incidental hepatocellular carcinoma after liver transplantation: population characteristics and outcomes. Transplant Proceedings2009;41(1):219-21.">Castillo 2009</a>; <a href="./references#CD014798-bbs2-0214" title="SenkerikovaR , FrankovaS , SperlJ , OliveriusM , KieslichovaE , FilipovaH , et al.Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation. Transplantation Proceedings2014;46(5):1426-9.">Senkerikova 2014</a>; <a href="./references#CD014798-bbs2-0187" title="MadalenoJ , AlvesR , SilvaN , CalretasS , TomeL , FerraoJ , et al.Incidentally discovered hepatocellular carcinoma in explanted liver: clinical, histopathologic features and outcome. Transplantation Proceedings2015;47(4):1051-4.">Madaleno 2015</a>; <a href="./references#CD014798-bbs2-0148" title="El MoghazyW , KashkoushS , MeebergG , KnetemanN .Incidence, characteristics, and prognosis of incidentally discovered hepatocellular carcinoma after liver transplantation. Journal of Transplantation2016;2016:1916387.">El Moghazy 2016</a>). </p> <p>The main hallmarks of HCC on an MRI study are non‐rim‐like hyperenhancement in the arterial phase, and washout in the portal‐venous and delayed phases. However, around 40% of HCCs present with atypical morphological features, which pose a significant diagnostic challenge for radiologists. This significant number of atypical HCCs may influence the sensitivity, and the radiologist should be acquainted to these atypical appearances to correctly interpret MRI findings. Another issue is the presence of HCC mimickers, such as intrahepatic cholangiocarcinoma, combined HCC‐cholangiocarcinoma, arterioportal shunt, or haemangioma in cirrhotic liver (<a href="./references#CD014798-bbs2-0173" title="LeeJH , LeeJM , KimSJ , BaekJH , YunSH , KimKW , et al.Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. British Journal of Radiology2012;85(101):e573-83.">Lee 2012b</a>; <a href="./references#CD014798-bbs2-0215" title="ShrikiJE , SeyalAR , DigheMK , YehMM , JalikisFG , AndeenNK , et al.CT of atypical and uncommon presentations of hepatocellular carcinoma. American Journal of Roentgenology2015;205(4):W411-23.">Shirki 2015</a>). </p> <p>The MRI accuracy estimates might only indirectly be compared with the results of CT obtained in a recent systematic review (<a href="./references#CD014798-bbs2-0196" title="NadarevicT , GiljacaV , ColliA , FraquelliM , CasazzaG , MileticD , et al.Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD013362. [DOI: 10.1002/14651858.CD013362.pub2]">Nadarevic 2021a</a>) showing a sensitivity of 77.5% (95% CI 70.9% to 82.9%) and a specificity of 91.3% (95% CI 86.5% to 94.5%). However, a direct comparison of the diagnostic modalities in the same participants is needed to support the choice between these techniques which depends also on their availability, costs, and risks. </p> <p>Overall, caution is needed in interpreting our review results as we judged all the studies at high risk of bias, and most of them with high concern regarding their applicability, mainly due to patient selection and reference standard domain. </p> </section> <h3 class="title" id="CD014798-sec-0075">Implications for research</h3> <section id="CD014798-sec-0075"> <p>Currently, available evidence on the diagnostic accuracy of MRI for diagnosis of HCC is inconclusive. Therefore, more high‐quality primary studies are needed. With the introduction of LI‐RADS criteria, there is no longer necessary to dichotomise results of MRI studies as these criteria also allow assessment of inconclusive and probable results. Apart from typical HCC appearances, atypical features of HCC need to be taken into consideration, so we hypothesise that further studies using Liver Imaging Reporting and Data System (LI‐RADS) positivity criteria may improve sensitivity. Also, it may be possible that including additional major features such as threshold growth, along with arterial hyperenhancement and subsequent washout, may improve sensitivity. Therefore, we welcome future cross‐sectional studies using score systems of positivity criteria. A direct comparison of MRI and CT as a second step in the clinical pathway for the diagnosis of HCC after ultrasound and alpha‐fetoprotein is also needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014798-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014798-sec-0008"></div> <div class="table" id="CD014798-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of MRI for the diagnosis of HCC in people with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting:</b> clinical setting (secondary or tertiary care setting) or surveillance programmes </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design:</b> cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index test:</b> MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition:</b> HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b> </p> <p> <ul id="CD014798-list-0001"> <li> <p>Pathology of the explanted liver in case of transplantation</p> </li> <li> <p>Histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up of ≥ 6 months to exclude the presence of focal lesions not detected by the index test </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence: risk of bias and applicability concerns</b> </p> <p> <ul id="CD014798-list-0002"> <li> <p>Participant selection: high/unclear risk of bias 26 studies (76%); high concern for applicability 20 studies (59%) </p> </li> <li> <p>Index tests: high/unclear risk of bias 4 studies (12%); high concern for applicability 1 study (3%) </p> </li> <li> <p>Reference standard: high/unclear risk of bias 28 studies (82%); high concern for applicability 16 studies (47%) </p> </li> <li> <p>Flow and timing: high/unclear risk of bias 31 studies (91%)</p> </li> <li> <p>Overall: high risk of bias all included studies; high concern for applicability 29 studies (85%) </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Findings</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Implications in a hypothetical cohort of 1000 people</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence</b><sup>a</sup><b>%</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True positives</b> will receive appropriate treatment (surgery or local ablative therapy or systemic chemotherapy) </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False negatives</b> will be misdiagnosed and not receive appropriate treatment </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True negatives</b> will not undergo inappropriate treatment or unnecessary further testing </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False positives</b> will undergo inappropriate treatment </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>34</p> <p>(4841)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>84.4% (80.1% to 87.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>93.8% (90.1% to 96.1%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HCC:</b> hepatocellular carcinoma; <b>MRI:</b> magnetic resonance imaging. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>We chose for exemplification three values of hepatocellular carcinoma prevalence: 36% for a population with low clinical suspicion, 56% as a median derived from our study analysis, and 66% for population with high clinical suspicion (assessment of nodules detected by ultrasound).<br/><sup>b</sup>Downgraded two levels for risk of bias and indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014798-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of resectable hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of MRI for the diagnosis of resectable HCC in people with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting:</b> clinical setting (secondary or tertiary care setting) or surveillance programmes </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design:</b> cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index test:</b> MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition:</b> resectable HCC </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b> </p> <p> <ul id="CD014798-list-0003"> <li> <p>Pathology of the explanted liver in case of transplantation</p> </li> <li> <p>Histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up of ≥ 6 months to exclude the presence of focal lesions not detected by the index test </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence: risk of bias and applicability concerns</b> (total 16 studies which had all participants with resectable HCC) </p> <p> <ul id="CD014798-list-0004"> <li> <p>Participant selection: high/unclear risk of bias 10 studies (63%); high concern for applicability 11 studies (69%) </p> </li> <li> <p>Index tests: high/unclear risk of bias 0 studies (0%); high concern for applicability 0 studies (0%) </p> </li> <li> <p>Reference standard: high/unclear risk of bias 10 studies (63%); high concern for applicability 11 studies (69%) </p> </li> <li> <p>Flow and timing: high/unclear risk of bias 14 studies (88%)</p> </li> <li> <p>Overall: high risk of bias; all included studies; high concern for applicability 11 studies (69%) </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Implications in a hypothetical cohort of 1000 people</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence</b><sup>a</sup><b>%</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True positives</b> will receive appropriate treatment (surgical resection) </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False negatives</b> will be misdiagnosed and not undergo surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True negatives</b> will not undergo inappropriate further testing or surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False positives</b> will undergo inappropriate further testing or surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16</p> <p>(2150)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>84.3% (77.6% to 89.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>92.9% (88.3% to 95.9%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HCC:</b> hepatocellular carcinoma; <b>MRI:</b> magnetic resonance imaging. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>We chose for exemplification three values of hepatocellular carcinoma prevalence: 36% for a population with low clinical suspicion, 56% as a median derived from our study analysis, and 66% for population with high clinical suspicion (assessment of nodules detected by ultrasound).<br/><sup>b</sup>Downgraded two levels for risk of bias and indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014798-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014798-sec-0009"></div> <p>Hepatocellular carcinoma (HCC) is the most common primary liver tumour, usually developing in the setting of chronic liver disease. It represents the third most common cause of death from cancer worldwide, with high rates in East and Southeast Asia, several areas of Africa, and Southern Europe (<a href="./references#CD014798-bbs2-0121" title="BertuccioP , TuratiF , CarioliG , RodriguezT , La VecchiaC , MalvezziM , et al.Global trends and predictions in hepatocellular carcinoma mortality. Journal of Hepatology2017;67(2):302-9.">Bertuccio 2017</a>). From the early 2010s, HCC was one of the few cancers that showed increasing incidence and mortality trends in several areas of the world including Europe, and North and Latin America (<a href="./references#CD014798-bbs2-0122" title="BosettiC , BertuccioP , MalvezziM , LeviF , ChatenoudL , NegriE , et al.Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Annals of Oncology2013;24:2657-71.">Bosetti 2013</a>; <a href="./references#CD014798-bbs2-0162" title="HashimD , BoffettaP , La VecchiaC , RotaM , BertuccioP , MalvezziM , et al.The global decrease in cancer mortality: trends and disparities. Annals of Oncology2016;27(5):926-33.">Hashim 2016</a>; <a href="./references#CD014798-bbs2-0210" title="RyersonAB , EhemanCR , AltekruseSF , WardJW , JemalA , ShermanRL , et al.Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer2016;122(9):1312-37.">Ryerson 2016</a>). Mortality rates, even with a recently downward reported trend, are reported to remain two to five times higher in Japan, Hong Kong, and Korea than in most European countries, and North and South America (<a href="./references#CD014798-bbs2-0121" title="BertuccioP , TuratiF , CarioliG , RodriguezT , La VecchiaC , MalvezziM , et al.Global trends and predictions in hepatocellular carcinoma mortality. Journal of Hepatology2017;67(2):302-9.">Bertuccio 2017</a>). Most common risk factors include liver cirrhosis, severe liver fibrosis, chronic infections with hepatitis B and C, heavy alcohol intake, tobacco use, diabetes, metabolic syndrome, aflatoxins (poisonous carcinogens produced by <i>Aspergillus flavus</i> and <i>Aspergillus parasiticus</i>, which grow in soil, decaying vegetation, hay, and grains), non‐alcoholic fatty liver disease, and being overweight (<a href="./references#CD014798-bbs2-0228" title="YangJD , HarmsenWS , SlettedahlSW , ChaiteerakijR , EndersFT , TherneauTM , et al.Factors that affect the risk for hepatocellular carcinoma and effects of surveillance. Clinical Gastroenterology and Hepatology2011;9(7):617-23.">Yang 2011</a>; <a href="./references#CD014798-bbs2-0123" title="BosettiC , TuratiF , La VecchiaC .Hepatocellular carcinoma epidemiology. Best Practice &amp; Research. Clinical Gastroenterology2014;28:753-70.">Bosetti 2014</a>; <a href="./references#CD014798-bbs2-0219" title="StanawayJD , FlaxmanAD , NaghaviM , FitzmauriceC , VosT , AbubakarI , et al.The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet2016;388(10049):1081-8.">Stanaway 2016</a>; <a href="./references#CD014798-bbs2-0121" title="BertuccioP , TuratiF , CarioliG , RodriguezT , La VecchiaC , MalvezziM , et al.Global trends and predictions in hepatocellular carcinoma mortality. Journal of Hepatology2017;67(2):302-9.">Bertuccio 2017</a>). People with HCC but without known risk factors have also been reported (<a href="./references#CD014798-bbs2-0125" title="BraletMP , RegimbeauJM , PineauP , DuboisS , LoasG , DegosF , et al.Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology2000;32(2):200-4.">Bralet 2000</a>; <a href="./references#CD014798-bbs2-0231" title="YoungAL , AdairR , PrasadKR , ToogoodGJ , LodgeJP .Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. Journal of the American College of Surgeons2012;214(2):174-83.">Young 2012</a>). HCC is rare among adolescents, with an incidence of 0.3 to 0.45 occurrences per million per year and accounts for less than 1% of all malignant neoplasms among children aged less than 20 years (<a href="./references#CD014798-bbs2-0189" title="MannJR , KasthuriN , RaafatF , PincottJR , ParkesSE , MuirKR , et al.Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatric and Perinatal Epidemiology1990;4(3):276-89.">Mann 1990</a>). The reported HCCs were associated with hepatitis B infection or with inherited metabolic disorders, specifically hereditary tyrosinaemia, alpha‐1‐antitrypsin deficiency, and glycogen storage disease type 1. Only approximately 30% of HCC in children are associated with cirrhosis, and the carcinogenesis and the clinical course are considered peculiar (<a href="./references#CD014798-bbs2-0199" title="NiYH , ChangMH , WangKJ , HsuHY , ChenHL , KaoJH , et al.Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology2004;127(6):1733-8.">Ni 2004</a>; <a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0194" title="MogulDB , LingSC , MurrayKF , SchwarzenbergSJ , RudzinskiER , SchwarzKB .Characteristics of hepatitis B virus-associated hepatocellular carcinoma in children: a multi-center study. Journal of Pediatric Gastroenterology and Nutrition2018;67(4):437-40.">Mogul 2018</a>). </p> <p>Clinically, HCC is frequently diagnosed in the late stages of liver disease because of the absence of specific symptoms, other than those related to chronic liver disease. Only less than 20% of patients are eligible for curative treatment – such as liver resection, transplantation, or ablation – due to advanced tumour stage, liver dysfunction, or shortage of liver donors (<a href="./references#CD014798-bbs2-0142" title="DavilaJA , DuanZ , McGlynnKA , El-SeragHB .Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. Journal of Clinical Gastroenterology2012;46:71-7.">Davila 2012</a>). Furthermore, curative treatment options are unfeasible in most people due to severe clinical deterioration at the moment of diagnosis, or due to the inaccuracy of the preoperative clinical evaluation and staging procedure. </p> <p>Despite the poor initial prognosis (the mortality‐to‐incidence overall ratio has been reported as 0.95 (<a href="./references#CD014798-bbs2-0152" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al.GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11. publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012 (accessed 26 February 2021).">Ferlay 2015</a>)), a five‐year survival of more than 50% can be achieved if HCC is detected at an early stage and relevant surgery conducted (<a href="./references#CD014798-bbs2-0155" title="FornerA , ReigM , BruixJ .Hepatocellular carcinoma. Lancet2018;391(10127):1301-14.">Forner 2018a</a>). According to the Barcelona Clinic Liver Cancer (BCLC) staging system, only people with early‐stage HCC are eligible for curative treatment (<a href="./references#CD014798-bbs2-0183" title="LlovetJM , BruC , BruixJ .Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease1999;19(3):329-38.">Llovet 1999</a>). Therefore, accurate and early diagnosis of HCC is of high importance. </p> <p>Prior to advancements in medical imaging, biopsy and cytological examination of the liver specimen were used to make a definitive diagnosis of HCC (<a href="./references#CD014798-bbs2-0221" title="TaoLC , HoCS , McLoughlinMJ , EvansWH , DonatEE .Cytologic diagnosis of hepatocellular carcinoma by fine-needle aspiration biopsy. Cancer1984;53(3):547-52.">Tao 1984</a>). With the development of advanced imaging techniques, HCC has become unique among tumours in that its characteristics can be accurately detected using imaging, thus reducing the need for invasive liver biopsy (<a href="./references#CD014798-bbs2-0055" title="FornerA , VilanaR , AyusoC , BianchiL , SoléM , AyusoJR , et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology2008;47(1):97-104. ">Forner 2008</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0188" title="ManiniMA , SangiovanniA , FornariF , PiscagliaF , BiolatoM , FanigliuloL , et al.Clinical and economical impact of 2012 AASLD guidelines for the diagnosis of hepatocellular carcinoma. Journal of Hepatology2014;60(5):995-1001.">Manini 2014</a>). Currently, biopsy is not preferred for the diagnosis of HCC due to concerns regarding tumour seeding, risks of bleeding, and high rate of false‐negative results (<a href="./references#CD014798-bbs2-0216" title="SilvaMA , HegabB , HydeC , GuoB , BuckelsJA , MirzaDF .Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut2008;57(11):1592-6.">Silva 2008</a>; <a href="./references#CD014798-bbs2-0205" title="PomfretEA , WashburnK , WaldC , NalesnikMA , DouglasD , RussoM , et al.Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplantation2010;16(3):262-78.">Pomfret 2010</a>). Therefore, biopsy is reserved for lesions with atypical appearance and when imaging results are equivocal (<a href="./references#CD014798-bbs2-0126" title="BruixJ , ShermanM .Management of hepatocellular carcinoma: an update. Hepatology2011;53(3):1020.">Bruix 2011</a>). </p> <p>Computed tomography (CT) and contrast‐enhanced magnetic resonance imaging (MRI) have been established as the non‐invasive imaging modalities for detection and evaluation of liver lesions (<a href="./references#CD014798-bbs2-0172" title="LeeJM , YoonJH , KimKW .Diagnosis of hepatocellular carcinoma: newer radiological tools. Seminars in Oncology2012;39:399-409.">Lee 2012a</a>; <a href="./references#CD014798-bbs2-0200" title="O'NeillEK , CogleyJR , MillerFH .The ins and outs of liver imaging. Clinics in Liver Disease2015;19(1):99-121.">O'Neill 2015</a>). In comparison with CT, MRI offers many advantages such as lack of ionising radiation, higher spatial resolution, ability to use both extracellular and hepatocellular contrast, and potentially better accuracy (<a href="./references#CD014798-bbs2-0161" title="HartwigV , GiovannettiG , VanelloN , LombardiM , LandiniL , SimiS .Biological effects and safety in magnetic resonance imaging: a review. International Journal of Environmental Research and Public Health2009;6(6):1778-98.">Hartwig 2009</a>; <a href="./references#CD014798-bbs2-0157" title="GroverVP , TognarelliJM , CrosseyMM , CoxIJ , Taylor-RobinsonSD , McPhailMJ .Magnetic resonance imaging: principles and techniques: lessons for clinicians. Journal of Experimental Hepatology2015;5(3):246-55.">Grover 2015</a>). Disadvantages are higher cost, longer imaging time, the need for patient co‐operation, patient claustrophobia, and contraindications related to paramagnetic implanted devices (<a href="./references#CD014798-bbs2-0200" title="O'NeillEK , CogleyJR , MillerFH .The ins and outs of liver imaging. Clinics in Liver Disease2015;19(1):99-121.">O'Neill 2015</a>). The ability of MRI to detect HCC rests on characterising the contrast enhancement patterns in arterial, portal venous, and subsequent phases relative to the surrounding liver tissue. The differences in blood flow and extracellular volume between HCC and normal liver tissue lead to main radiological hallmarks of HCC (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). </p> <p>According to the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) guidelines, a single contrast enhanced imaging study (CT or MRI), showing typical radiological hallmarks in people with cirrhosis, is valid to diagnose HCC (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). However, if a detected lesion presents with some (but not all) of the hallmarks of HCC, another imaging study or biopsy is warranted (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). </p> <p>According to current relevant guidelines, there are some differences in recommendations for management with regards to the size of a suspected focal liver lesion. In AASLD guidelines, lesions with a diameter 1 cm or less and those with a diameter more than 1 cm without HCC hallmarks are labelled as indeterminate lesions and require follow‐up (<a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). EASL guidelines propose a diagnostic algorithm for management of suspected focal liver lesions and group lesions in two categories with a diameter of 1 cm or less, and more than 1 cm (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). Asian Pacific Association for the Study of the Liver (APASL) diagnostic pathways focus more on lesion characteristics than on their size (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>). AASLD, EASL, and APASL guideline recommendations do not encompass children and adolescents (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). </p> <p>Previous systematic reviews and reviews have assessed the performance of MRI in detecting HCC, and they have included different studies and yielded different results (<a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD014798-bbs2-0170" title="KimSH , ChoiBI , LeeJY , KimSJ , SoYH , EunHW , et al.Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology2008;51(Suppl 1):52-60.">Kim 2008</a>; <a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a>; <a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a>; <a href="./references#CD014798-bbs2-0154" title="FlorianiI , D'OnofrioM , RulliE , ChenMH , LiR , MusiccoL .Performance of imaging modalities in the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ultraschall in der Medizin2013;34:454-62.">Floriani 2013</a>; <a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a>; <a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a>; <a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>; <a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a>; <a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a>; <a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a>; <a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a>; <a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a>; <a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a>; <a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a>; <a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a>). These reviews assessed MRI either as a stand‐alone test or compared MRI with CT and ultrasonography. Evaluation of risk of bias and inclusion criteria, type of studies, and reference standards were often inconsistent and questionable. Furthermore, these reviews did not put the index tests into context and did not clearly define their role. Instead, they compared all the available tests as they were used simultaneously. The aim of this systematic review and meta‐analysis is to use Cochrane methodology to determine the accuracy of MRI using either extracellular or hepatocellular contrast agent for the diagnosis of HCC of any size, as well as to identify resectable HCC in adults with chronic liver disease. </p> <section id="CD014798-sec-0010"> <h3 class="title" id="CD014798-sec-0010">Target condition being diagnosed</h3> <section id="CD014798-sec-0011"> <h4 class="title">Hepatocellular carcinoma</h4> <p>HCC is the most common primary liver cancer which occurs mostly in people with chronic liver disease. The incidence of HCC increases in people with hepatitis B and C, alcohol use, and non‐alcoholic fatty liver disease, and those with liver cirrhosis of various aetiologies (<a href="./references#CD014798-bbs2-0126" title="BruixJ , ShermanM .Management of hepatocellular carcinoma: an update. Hepatology2011;53(3):1020.">Bruix 2011</a>). There is no definite threshold in the definition of lesion size, although literature tends to classify lesions with a diameter of 2 cm or less as 'small' (<a href="./references#CD014798-bbs2-0166" title="HussainSM , ZondervanPE , IJzermansJN , SchalmSW , deManRA , KrestinGP .Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics2002;22(5):1026-39.">Hussain 2002</a>; <a href="./references#CD014798-bbs2-0133" title="ChoiJY , LeeJM , SirlinCB .CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.">Choi 2014a</a>; <a href="./references#CD014798-bbs2-0203" title="ParkHJ , ChoiBI , LeeES , ParkSB , LeeJB .How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer2017;6(3):189-203.">Park 2017</a>). </p> <p>In clinical practice and according to pertinent guidelines, multiphasic CT or MRI with intravascular contrast allow for a highly accurate diagnosis of HCC without an invasive biopsy. The diagnosis of HCC is usually obtained on the basis of cross‐sectional CT or MRI features, and liver histology is required only for undefined lesions (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>; <a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). </p> <p>Several staging systems for HCC have been proposed and developed; however, there is no globally applicable staging system (<a href="./references#CD014798-bbs2-0171" title="KinoshitaA , OnodaH , FushiyaN , KoikeK , NishinoH , TajiriH .Staging systems for hepatocellular carcinoma: current status and future perspectives. World Journal of Hepatology2015;7(3):406-24.">Kinoshita 2015</a>). Among different staging protocols, the BCLC staging system has a notable feature of treatment recommendations for each stage based on the best treatment options currently available (<a href="./references#CD014798-bbs2-0183" title="LlovetJM , BruC , BruixJ .Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease1999;19(3):329-38.">Llovet 1999</a>; <a href="./references#CD014798-bbs2-0184" title="LlovetJM , BurroughsA , BruixJ .Hepatocellular carcinoma. Lancet2003;362(9399):1907-17.">Llovet 2003</a>; <a href="./references#CD014798-bbs2-0185" title="LlovetJM , Di BisceglieAM , BruixJ , KramerBS , LencioniR , ZhuAX , et al.Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute2008;100(10):698-711.">Llovet 2008</a>). It is comprised of four elements: tumour extension, liver functional reserve, physical status, and cancer‐related symptoms. According to the BCLC, only people with early‐stage HCC are eligible for curative treatment such as surgical resection or percutaneous treatment. Orthotopic liver transplantation (OLT) is reserved for people with decompensated cirrhosis, and it is considered a definite curative treatment for HCC. The early experience with OLT for HCC in the 1980s included initial poor five‐year survival and high recurrence rates, leading to OLT being contraindicated in HCC (<a href="./references#CD014798-bbs2-0230" title="YokoyamaI , TodoS , IwatsukiS , StarzlTE .Liver transplantation in the treatment of primary liver cancer. Hepato-gastroenterology1990;37(2):188-93.">Yokoyama 1990</a>). In 1996, specific criteria were developed for selection of people with HCC for OLT, which became known as the Milan criteria (<a href="./references#CD014798-bbs2-0190" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334(11):693-9.">Mazzaferro 1996</a>). These criteria have been repeatedly validated and their value is considerable (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). With their implementation, the overall five‐year survival of people after OLT exceeded 70% (<a href="./references#CD014798-bbs2-0191" title="MazzaferroV , BhooriS , SpositoC , BonginiM , LangerM , MiceliR , et al.Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence based analysis of 15 years of experience. Liver Transplantation2011;17(Suppl 2):S44-57.">Mazzaferro 2011</a>). The criteria for patients eligible for OLT include single HCC lesion with diameter of 5 cm or less; or up to three HCC lesions, each with diameter of 3 cm or less; no vascular invasion, and no extrahepatic involvement (no metastasis) (<a href="./references#CD014798-bbs2-0190" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334(11):693-9.">Mazzaferro 1996</a>; <a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). </p> </section> </section> <section id="CD014798-sec-0012"> <h3 class="title" id="CD014798-sec-0012">Index test(s)</h3> <p>MRI is an advanced imaging modality that uses magnetic fields, magnetic field gradients, and radio waves to produce images of tissues and organs. Since the early 2010s, it was established as a powerful clinical tool for liver imaging offering relevant answers to specific clinical questions (<a href="./references#CD014798-bbs2-0147" title="EdelmanRR .The history of MR imaging as seen through the pages of radiology. Radiology2014;273(2 Suppl):S181-200.">Edelman 2014</a>; <a href="./references#CD014798-bbs2-0225" title="XianJF , ChenM , JinZY .Magnetic resonance imaging in clinical medicine: current status and potential future developments in China. Chinese Medical Journal2015;128(5):569-70.">Xian 2015</a>). Magnetic field strength of 1.5 or 3.0 Tesla is currently sufficient for standard clinical practice. In the context of liver imaging and focal liver lesion characterisation, the morphology is assessed by analysing specific features on different MRI sequences. </p> <p>In MRI, the use of contrast agents is frequently necessary. Most commonly used types of contrast agents are gadolinium‐based compounds, while other infrequently used contrasts include manganese‐based, iron oxide, and iron platinum agents (<a href="./references#CD014798-bbs2-0226" title="XiaoYD , PaudelR , LiuJ , MaC , ZhangZS , ZhouSK .MRI contrast agents: classification and application (review). International Journal of Molecular Medicine2016;38(5):1319-26.">Xiao 2016</a>). In clinical practice, two main types of gadolinium‐based contrast agents are used in liver imaging: extracellular contrast agents (ECA) and hepatobiliary contrast agents (HBA). ECAs are most widely used, as they allow the acquisition of arterial, portal venous, and delayed phases. HBAs provide similar information as ECAs, with the unique functional information on hepatocyte uptake provided in additional delayed hepatotropic phase (<a href="./references#CD014798-bbs2-0134" title="ChoiJY , LeeJM , SirlinCB .CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology2014;273(1):30-50.">Choi 2014b</a>; <a href="./references#CD014798-bbs2-0200" title="O'NeillEK , CogleyJR , MillerFH .The ins and outs of liver imaging. Clinics in Liver Disease2015;19(1):99-121.">O'Neill 2015</a>). When performing an MRI examination using ECA, morphological criteria for a definite HCC include non‐rim‐like hyperenhancement in the late arterial phase, and subsequent non‐peripheral washout in the portal‐venous phase or delayed phase. These criteria assess the vascular pattern of the lesions, emphasising the presence of hypervascularity of the tumour tissue. In the context of an MRI examination using HBA, the additional hepatotropic phase provides information on the parenchymal status of the lesion. Altered hepatocytes lose the ability to take up the contrast, so the lesion is hypointense relative to enhanced normal liver parenchyma (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). </p> <p>In 2011, the American College of Radiology introduced a comprehensive system and criteria for diagnosing HCC, due to the need for accurate and structured non‐invasive interpretation of suspected liver lesions (<a href="./references#CD014798-bbs2-0149" title="ElsayesKM , KielarAZ , ChernyakV , MorshidA , FurlanA , MaschWR , et al.LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. Journal of Hepatocellular Carcinoma2019;6:49-69.">Elsayes 2019</a>). According to the latest version from 2018, eight categories exist ranging from definite benign lesions to a definite HCC lesion (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). Major features for HCC include non‐rim‐like arterial hyperenhancement, non‐peripheral washout, enhancing capsule, lesion size (cut‐off values of 10 mm or 20 mm), and threshold growth (size increase of a mass by 50% or greater in six months or less) (<a href="./references#CD014798-bbs2-0132" title="ChernyakV , FowlerKJ , KamayaA , KielarAZ , ElsayesKM , BashirMR , et al.Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology2018;289(3):816-30.">Chernyak 2018</a>). Depending on the presence of major and ancillary features, the lesion is characterised as Liver Imaging Reporting and Data System (LI‐RADS) 1 to 5, with LR‐TIV representing tumour in vein, and LR‐M representing probable or definite malignancy, but not specific HCC (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). LI‐RADS 4 refers to probable HCC, and LI‐RADS 5 refers to definite HCC (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). In practice, lesion diameter and threshold growth are not universally accepted, contributing to heterogeneity of the use of positivity criteria in centres worldwide (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). </p> </section> <section id="CD014798-sec-0013"> <h3 class="title" id="CD014798-sec-0013">Clinical pathway</h3> <p>Surveillance for HCC (i.e. screening performed at regular intervals) in the at‐risk population (people with chronic liver disease regardless of aetiology) is carried out by abdominal ultrasound (US) for detection of liver nodules (<a href="./references#CD014798-bbs2-0168" title="KanwalF , SingalAG .Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology2019;157(1):54-64.">Kanwal 2019</a>). Once a suspected nodule has been detected, other imaging methods are considered, according to the size of the nodule and appropriate guidelines (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). <a href="#CD014798-fig-0001">Figure 1</a> presents the clinical pathway showing how the tests are used. US and alpha‐fetoprotein (AFP) serum measurement, alone or in combination, are used as a triage test before CT and MRI. CT and MRI play a role of add‐on tests to confirm the diagnosis and to stage the disease. Only in the case of focal lesion greater than 2 cm and without diagnostic hallmarks for HCC on CT and MRI, is a biopsy recommended. Lesions with a diameter less than 1 cm and those with a diameter of 1 cm to 2 cm without HCC hallmarks are labelled as indeterminate lesions and require follow‐up (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). </p> <div class="figure" id="CD014798-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of the diagnostic pathway for the diagnosis of hepatocellular carcinoma." data-id="CD014798-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of the diagnostic pathway for the diagnosis of hepatocellular carcinoma.</p> </div> </div> </div> <p>The diagnostic pathway after the detection of a focal liver lesion is only minimally variable among the different scientific societies as reviewed below. </p> <section id="CD014798-sec-0014"> <h4 class="title">American Association for the Study of Liver Disease diagnostic guidelines</h4> <p>According to AASLD guidelines, it is recommended that further diagnostic workup of people suspected of having HCC is performed with either multiphasic CT or multiphasic MRI because of their similar diagnostic performance. There is no agreement about which diagnostic test to use: multiphasic CT with extracellular agents, multiphasic MRI with extracellular agents, and multiphasic MRI with hepatocellular contrast agent. Although it is not widely used in North America, contrast‐enhanced ultrasound (CEUS) can be used to diagnose HCC. In case of indeterminate imaging findings on CT and MRI, several options are available, such as follow‐up imaging, imaging with an alternative modality or alternative contrast agent, or biopsy, but no option can be recommended over another (<a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). </p> </section> <section id="CD014798-sec-0015"> <h4 class="title">European Association for the Study of the Liver diagnostic guidelines</h4> <p>In cirrhosis or advanced chronic liver disease, the EASL proposed diagnostic algorithm divides suspected focal liver lesions into two categories: lesions smaller than 1 cm, and those larger than 1 cm in diameter. Lesions smaller than 1 cm are to be followed up by US every four months: if the size of the lesion did not increase, then further US follow‐up is recommended, otherwise multiphasic contrast‐enhanced CT, multiphasic contrast‐enhanced MRI, or gadoxetic‐enhanced MRI is required. Lesions larger than 1 cm directly require to be evaluated by CT or MRI. If at least one of these imaging modalities is positive (i.e. confirms the existence of HCC hallmarks), diagnosis of HCC is considered certain. If the results are equivocal, the use of other multiphasic imaging modality is required: multiphasic contrast‐enhanced CT or multiphasic contrast‐enhanced MRI, gadoxetic‐enhanced MRI, or CEUS. If these studies confirm the hallmarks of HCC, the diagnosis is certain, otherwise biopsy is warranted. If biopsy appears to be unclear, repeat biopsy is to be considered or a repeat US follow‐up every four months (<a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>). </p> </section> <section id="CD014798-sec-0016"> <h4 class="title">Asian Pacific Association for the Study of the Liver diagnostic guidelines</h4> <p>Under the APASL guidelines, a single dynamic contrast‐enhanced MRI or CT is warranted regardless of the size of suspected liver nodule. If typical hallmarks of HCC are shown (presence of arterial hyperenhancement, followed by washout in the portal venous phase or delayed phase, or both), diagnosis is confirmed. If the lesion is hypervascular but shows no washout, another contrast‐enhanced MRI is needed. If the lesion proves to be hypointense, HCC diagnosis is confirmed; however, if the lesion is iso‐ or hyperintense, biopsy is warranted. If the lesion on the first dynamic MRI or CT is non‐hypervascular, a dynamic MRI study in hepatobiliary phase is needed. If the lesion is iso‐ or hyperintense, surveillance by US is recommended every six months, and if the lesion is hypointense, CEUS of the liver nodule is warranted. Depending on lesion features on CEUS, biopsy, or another dynamic CT or MRI study is recommended every three to six months (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>). </p> </section> <section id="CD014798-sec-0017"> <h4 class="title">Prior test(s)</h4> <p>US is recommended as a triage test in people at risk for developing HCC in surveillance programmes or suspected of having HCC in clinical settings (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>). When US detects a focal lesion suspected of HCC, MRI should be performed to confirm the diagnosis. Moreover, when US, CT, or CEUS detect liver nodules that are not diagnostic for HCC, MRI can be used for further diagnosis prior to histology. AFP, a glycoprotein assessed in serum as a tumour marker, can also be used prior to MRI to assess the malignancy of a focal liver lesion. </p> <p>The diagnosis of the underlying chronic liver disease is based on clinical judgement derived from history, laboratory testing, physical examination, imaging, liver stiffness measurement, liver histology, or a combination of these. Due to the accuracy of non‐invasive tests, liver histology is reserved to only a minority of patients with unclear diagnosis and a non‐invasive diagnosis of advanced chronic liver disease is considered equivalent to a histological diagnosis of cirrhosis (<a href="./references#CD014798-bbs2-0143" title="deFranchisR .Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. Journal of Hepatology2015;63:743-52.">de Franchis 2015</a>). </p> </section> <section id="CD014798-sec-0018"> <h4 class="title">Alternative test(s)</h4> <section id="CD014798-sec-0019"> <h5 class="title">Contrast‐enhanced ultrasound</h5> <p>CEUS is an advanced form of US examination in which images are acquired using intravenously injected microbubble contrast agent (<a href="./references#CD014798-bbs2-0202" title="PangEH , ChanA , HoSG , HarrisAC .Contrast-enhanced ultrasound of the liver: optimizing technique and clinical applications. American Journal of Radiology2018;210(2):320-32.">Pang 2018</a>). Dynamic CEUS images are obtained similarly to contrast‐enhanced CT and MRI studies: depending on the time of image acquisition after intravenous contrast injection, the diagnostic examination differentiates arterial and portal venous phases in which sonographic hallmarks for HCC, such as arterial hyperenhancement and subsequent washout appearance, are investigated (<a href="./references#CD014798-bbs2-0136" title="ChungYE , KimKW .Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography2015;34(1):3-18.">Chung 2015</a>; <a href="./references#CD014798-bbs2-0179" title="American College of Radiology.Liver imaging reporting and data system. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf (accessed 7 July 2020).">LI‐RADS 2017</a>). Unlike CT and MRI contrasts, US contrast agent is a purely intravascular agent; therefore, it is highly accurate in detecting tumour angiogenesis (<a href="./references#CD014798-bbs2-0211" title="SchirnerM , MenradA , StephensA , FrenzelT , HauffP , LichaK .Molecular imaging of tumor angiogenesis. Annals of the New York Academy of Sciences2004;1014:67-75.">Schirner 2004</a>). The use of US contrast agents, in particular sulphur hexafluoride microbubbles, is generally considered safe, with the reported incidence of adverse reactions of less than 0.02% (<a href="./references#CD014798-bbs2-0204" title="PiscagliaF , BolondiL .The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology2006;32(9):1369-75.">Piscaglia 2006</a>; <a href="./references#CD014798-bbs2-0220" title="TangC , FangK , GuoY , LiR , FanX , ChenP , et al.Safety of sulfur hexafluoride microbubbles in sonography of abdominal and superficial organs: retrospective analysis of 30,222 cases. Journal of Ultrasound in Medicine2017;36(3):531-8.">Tang 2017</a>). In comparison, the adverse event proportion for iodine‐based contrast agent ranges from 1% to 12%, and for gadolinium‐based contrast agents ranges from 0.07% to 2.4% (<a href="./references#CD014798-bbs2-0124" title="BottinorW , PolkampallyP , JovinI .Adverse reactions to iodinated contrast media. International Journal of Angiology2013;22:149-54.">Bottinor 2013</a>; <a href="./references#CD014798-bbs2-0192" title="McDonaldJS , HuntCH , KolbeAB , SchmitzJJ , HartmanRP , MaddoxDE , et al.Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281945 injections. Radiology2019;292(3):620-7.">McDonald 2019</a>; <a href="./references#CD014798-bbs2-0118" title="ACR Committee on Drugs and Contrast Media.ACR manual on contrast media. www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (accessed 26 February 2021).">ACR 2021</a>). In the context of liver lesion imaging, CEUS is considered more cost‐effective than CT or MRI (<a href="./references#CD014798-bbs2-0217" title="SirliR , SporeaI , MartieA , PopescuA , DanilaM .Contrast enhanced ultrasound in focal liver lesions – a cost-efficiency study. Medical Ultrasonography2010;12(4):280-5.">Sirli 2010</a>; <a href="./references#CD014798-bbs2-0222" title="WestwoodM , JooreM , GruttersJ , RedekopK , ArmstrongN , LeeK , et al.Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technology Assessment2013;17(16):1-243.">Westwood 2013</a>; <a href="./references#CD014798-bbs2-0218" title="SmajerovaM , PetrasovaH , LittleJ , OvesnaP , AndrasinaT , ValekV , et al.Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis. World Journal of Gastroenterology2016;22(38):8605-14.">Smajerova 2016</a>). </p> </section> <section id="CD014798-sec-0020"> <h5 class="title">Computed tomography</h5> <p>Contrast‐enhanced multiphasic multidetector CT is a non‐invasive imaging modality for detection and evaluation of liver lesions (<a href="./references#CD014798-bbs2-0150" title="FederleMP , BlacharA .CT evaluation of the liver: principles and techniques. Seminars in Liver Disease2001;21(2):135-45.">Federle 2001</a>). The ability to detect HCC rests on characterising the enhancement patterns in arterial, portal venous, and subsequent phases relative to the surrounding liver tissue (<a href="./references#CD014798-bbs2-0198" title="NavinPJ , VenkateshSK .Hepatocellular carcinoma: state of the art imaging and recent advances. Journal of Clinical and Translational Hepatology2019;7(1):72-85.">Navin 2019</a>). The differences in blood flow and extracellular volume between HCC tissue and normal liver tissue lead to main radiological hallmarks such as homogeneous (non‐rim‐like) arterial phase hyperenhancement suggesting tumoural neo‐angiogenesis and subsequent non‐peripheral washout with enhancing capsule in later phases, suggesting the presence of arteriovenous communications (<a href="./references#CD014798-bbs2-0164" title="HennedigeT , VenkateshSK .Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging2013;12(3):530-47.">Hennedige 2013</a>; <a href="./references#CD014798-bbs2-0133" title="ChoiJY , LeeJM , SirlinCB .CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.">Choi 2014a</a>; <a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). CT is a commonly used modality for diagnosing HCC due to its short acquisition time and high spatial resolution. The obvious downfall of CT is the use of ionising radiation, which is harmful for tissues and organs on a molecular level. Although the damage is quickly repaired, occasional misrepair can induce mutations, gene fusion, and chromosomal translocations, all of which could lead to the development of cancer (<a href="./references#CD014798-bbs2-0193" title="MitelmanF , JohanssonB , MertensF , editor(s).Mitelman database of chromosome aberrations and gene fusions in cancer. mitelmandatabase.isb-cgc.org (accessed 14 October 2020).">Mitelman 2018</a>). Iodine‐based contrast agents may also be damaging to tissues and organs resulting in acute or late adverse reactions of different severity (<a href="./references#CD014798-bbs2-0120" title="BeckettKR , MoriarityAK , LangerJM .Safe use of contrast media: what the radiologist needs to know. Radiographics2015;35(6):1738-50.">Beckett 2015</a>). </p> </section> </section> </section> <section id="CD014798-sec-0021"> <h3 class="title" id="CD014798-sec-0021">Rationale</h3> <p>A suspected HCC liver lesion is currently detected by liver US in people with normal or high AFP levels during surveillance programmes in people with chronic liver disease. Following US, the diagnosis of HCC is usually confirmed with CEUS, CT, or MRI. CT and MRI are also appropriate for staging of HCC and allow the choice of the most appropriate treatment. There is no clear evidence of the benefits of surveillance programmes in terms of overall survival: the conflicting results can be a consequence of an inaccurate detection, ineffective treatment, or both. Assessing the diagnostic accuracy of MRI and CT as two confirmatory tests after triage tests (US, AFP, or their combination), may clarify whether the absence of benefit in surveillance programmes might be related to underdiagnosing or understaging. Furthermore, an assessment of the accuracy of MRI for the diagnosis of HCC is also needed for ruling out, diagnosing, or supporting further testing in people with chronic liver disease who are not included in surveillance programmes. </p> <p>This review represents part of a series of systematic reviews about the diagnostic accuracy of the most commonly used modalities for diagnosing HCC in adults with chronic liver disease. The first review includes assessment of the diagnostic accuracy of US and AFP levels, which are used as triage tests in surveillance (<a href="./references#CD014798-bbs2-0140" title="ColliA , NadarevicT , MileticD , GiljacaV , FraquelliM , ŠtimacD , et al.Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews2021, Issue 4. Art. No: CD013346. [DOI: 10.1002/14651858.CD013346.pub2]">Colli 2021</a>). The second review will focus on the diagnostic accuracy of CEUS in characterising suspected lesions as HCC as a second‐line diagnostic modality (<a href="./references#CD014798-bbs2-0156" title="FraquelliM , NadarevicT , GiljacaV , ColliA , MileticD , ŠtimacD , et al.Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD013483. [DOI: 10.1002/14651858.CD013483]">Fraquelli 2019</a>). The third review focuses on the assessment of CT as a third‐line imaging modality in assessing focal liver lesions detected on US suspected for HCC (<a href="./references#CD014798-bbs2-0196" title="NadarevicT , GiljacaV , ColliA , FraquelliM , CasazzaG , MileticD , et al.Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD013362. [DOI: 10.1002/14651858.CD013362.pub2]">Nadarevic 2021a</a>). The current fourth review analyses the accuracy of MRI for diagnosing HCC using different types of contrast media. Once these reviews are completed and published, we plan to design an overarching review comparing the accuracy of CEUS, CT, and MRI for the diagnosis and staging of HCC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014798-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014798-sec-0022"></div> <p>To assess the diagnostic accuracy of magnetic resonance imaging for the diagnosis of hepatocellular carcinoma of any size and at any stage in adults with chronic liver disease. </p> <section id="CD014798-sec-0023"> <h3 class="title" id="CD014798-sec-0023">Secondary objectives</h3> <p>To assess the diagnostic accuracy of MRI for the diagnosis of resectable HCC in adults with chronic liver disease. </p> <p>To identify potential sources of heterogeneity, we plan to investigate the effects of the following variables: study date; inclusion of people without cirrhosis; study location (population differences); participant selection; different HCC stages; different reference standards; different liver cirrhosis aetiologies; differences in prior testing; predefinition of magnetic resonance (MR) positivity criteria; and type of contrast media (see <a href="#CD014798-sec-0041">Investigations of heterogeneity</a>). </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014798-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014798-sec-0024"></div> <section id="CD014798-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014798-sec-0026"> <h4 class="title">Types of studies</h4> <p>We included studies that, irrespective of publication status and language, evaluated the diagnostic accuracy of MRI for the diagnosis of HCC in adults with chronic liver disease. These studies should have used one of the acceptable reference standards (see <a href="#CD014798-sec-0031">Reference standards</a>). </p> <p>We considered studies of cross‐sectional design only if they included participants with clinical suspicion of HCC. We excluded two‐gate design studies (<a href="./references#CD014798-bbs2-0144" title="DeeksJJ , BossuytPM , LeeflangM , TakwoingiY , FlemyngE , MellorL .Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. London: Cochrane. Available from training.cochrane.org/handbook-diagnostic-test-accuracy/PDF/v2.">DTA Handbook 2021</a>), that compared people with known HCC to matched controls as these studies are considered to have high risk of bias due to inflated accuracy estimates (<a href="./references#CD014798-bbs2-0139" title="ColliA , FraquelliM , CasazzaG , ConteD , NikolovaD , DucaP , et al.The architecture of diagnostic research: from bench to bedside – research guidelines using liver stiffness as an example. Hepatology2014;60(1):408-18.">Colli 2014</a>). We included studies assessing MRI if all the participants had undergone testing with at least one of the acceptable reference standards. We excluded studies that analysed data only per lesion, rather than per participant, unless study authors made available per‐participant data. </p> </section> <section id="CD014798-sec-0027"> <h4 class="title">Participants</h4> <p>We included studies with adults (aged 16 years and above), with chronic liver disease, irrespective of aetiology, severity of disease, and duration of illness, with suspicion of having HCC based on prior tests, US or AFP, or both. The review focused on diagnostic questions related to adults with a first diagnosis of HCC. </p> <section id="CD014798-sec-0028"> <h5 class="title">Exclusion criteria</h5> <p>Adults with previous diagnosis and treatment of HCC make up a distinct group for which the diagnosis or natural history of HCC has been modified. These people were not the focus of this review; therefore, we excluded studies that included such participants unless they represented less than 5% of all the included participants, or if investigators had presented data in such a way as to allow this group of participants to be isolated from the remaining included participants. </p> </section> </section> <section id="CD014798-sec-0029"> <h4 class="title">Index tests</h4> <p>MRI for the detection of HCC with the use of ECA or HBA, or both. Regarding positivity criteria, we accepted any definition of positivity explained in the studies. </p> </section> <section id="CD014798-sec-0030"> <h4 class="title">Target conditions</h4> <p> <ul id="CD014798-list-0005"> <li> <p>HCC of any size and at any stage.</p> </li> <li> <p>Resectable HCC (see <a href="#CD014798-sec-0023">Secondary objectives</a>). The definition of resectable HCC is a neoplasm amenable to surgical radical resection according to the current guidelines (<a href="./references#CD014798-bbs2-0201" title="OmataM , ChengAL , KokudoN , KudoM , LeeJM , JiaJ , et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International2017;11(4):317-70.">Omata 2017</a>; <a href="./references#CD014798-bbs2-0146" title="GallePR , FornerA , LlovetJM , MazzaferroV , PiscagliaF , RaoulJL , et al.EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology2018;69(1):182-236.">EASL 2018</a>; <a href="./references#CD014798-bbs2-0163" title="HeimbachJK , KulikLM , FinnRS , SirlinCB , AbecassisMM , RobertsLS , et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology2018;67(1):358-80.">Heimbach 2018</a>): a single lesion with a maximum diameter of less than 5 cm, or fewer than three lesions with a maximum diameter of 3 cm (<a href="./references#CD014798-bbs2-0190" title="MazzaferroV , RegaliaE , DociR , AndreolaS , PulvirentiA , BozzettiF , et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine1996;334(11):693-9.">Mazzaferro 1996</a>). </p> </li> </ul> </p> </section> <section id="CD014798-sec-0031"> <h4 class="title">Reference standards</h4> <p>We accepted as a reference standard for the diagnosis of HCC one of the following:</p> <p> <ul id="CD014798-list-0006"> <li> <p>the pathology of the explanted liver in case of transplantation;</p> </li> <li> <p>the histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up period of at least six months using periodic testing with US, AFP CT, or MRI. to exclude the presence of focal lesions not detected by the index test. </p> </li> </ul> </p> <p>These two reference standards are not perfect. The pathology of the explanted liver is possible only in the case when all the included participants undergo liver transplantation; therefore, the setting does not correspond to the clinical question that only people with advanced and decompensated liver disease are candidates for OLT (<a href="./references#CD014798-bbs2-0145" title="European Association for the Study of the Liver.EASL Clinical Practice Guidelines: liver transplantation. Journal of Hepatology2016;64(2):433-85.">EASL 2016</a>). In the case of histology of resected focal lesion and histology of biopsied liver lesions, the negative result can be confirmed only with an adequate follow‐up using periodic testing with US, AFP, CT, or MRI (<a href="./references#CD014798-bbs2-0197" title="NathaniP , GopalP , RichN , YoppA , YokooT , JohnB , et al.Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut2021;70(2):401-7.">Nathani 2021</a>). Therefore, differential verification is unavoidable in this context (<a href="./references#CD014798-bbs2-0178" title="LijmerJG , MolBW , HeisterkampS , BonselGJ , PrinsMH , van derMeulenJH , et al.Empirical evidence of design-related bias in studies of diagnostic tests. Journal of the American Medical Association1999;282(11):1061-6.">Lijmer 1999</a>). </p> </section> </section> <section id="CD014798-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014798-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group (CHBG) Controlled Trials Register and the CHBG Diagnostic Test of Accuracy Studies Register (the CHBG Information Specialist searched both registers via the Cochrane Register of Studies Web on 9 November 2021), the Cochrane Library (2021, Issue 11), MEDLINE Ovid (1946 to 9 November 2021), Embase Ovid (1974 to 9 November 2021), LILACS (Bireme; 1982 to 9 November 2021), Science Citation Index – Expanded (Web of Science; 1900 to 9 November 2021), and Conference Proceedings Citation Index – Science (Web of Science; 1990 to 9 November 2021) using the search strategies shown in <a href="./appendices#CD014798-sec-0080">Appendix 1</a>. We ran the searches on 24 February 2021, and then we reran them on 9 November 2021. We used the Cochrane Register of Studies Web for managing search results from the electronic searches and for identifying duplicates. </p> <p>We applied no restrictions on language or document type.</p> </section> <section id="CD014798-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We tried to identify additional references by manually searching articles retrieved from digital databases and relevant review articles. We sought information on unpublished studies by contacting experts in the field. In addition, we handsearched abstract books from meetings of the AASLD, EASL, and APASL held during the 10 years prior to the search date (9 November 2021). We also searched for other types of grey literature in the System for Information on Grey Literature in Europe 'OpenGrey' (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>) on 9 November 2021. Further information was requested by contacting authors of studies by e‐mail. </p> </section> </section> <section id="CD014798-sec-0035"> <h3 class="title" id="CD014798-sec-0035">Data collection and analysis</h3> <p>We followed available guidelines as provided in <i>theCochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD014798-bbs2-0144" title="DeeksJJ , BossuytPM , LeeflangM , TakwoingiY , FlemyngE , MellorL .Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. London: Cochrane. Available from training.cochrane.org/handbook-diagnostic-test-accuracy/PDF/v2.">DTA Handbook 2021</a>). </p> <section id="CD014798-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (VG and TN) independently scrutinised titles and abstracts identified by electronic literature searching to identify potentially eligible studies. We selected any citation, identified by either of the two review authors, as potentially eligible for full‐text review. The same review authors independently assessed full‐text papers for study eligibility, using predefined inclusion and exclusion criteria. We resolved any discrepancies by discussion. We identified and excluded duplicates and collated multiple reports of the same study, so that each study rather than each report, was the unit of interest in the review. We recorded all studies after full‐text assessment, and their reasons for exclusion, in the <a href="./references#CD014798-sec-0091" title="">Characteristics of excluded studies</a> table and illustrated the study selection process using a PRISMA diagram (<a href="./references#CD014798-bbs2-0195" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG .Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097.">Moher 2009</a>). </p> </section> <section id="CD014798-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>We developed a standardised data extraction form and piloted the form on five included studies before finalising it. Then, two review authors (VG and TN) completed a piloted data extraction form for each included study. Each review author independently retrieved study data. In cases of disagreement, we reached consensus through discussion with a third review author (GC). We extracted the following data and completed a <a href="./references#CD014798-sec-0090" title="">Characteristics of included studies</a> table: </p> <p> <ul id="CD014798-list-0007"> <li> <p>general information: title, journal, year, publication type, and study design (prospective versus retrospective), surveillance programme, or clinical cohort; </p> </li> <li> <p>sample size: number of participants meeting the criteria and total number of participants included and tested; </p> </li> <li> <p>baseline characteristics: baseline diagnosis, age, sex, presence of cirrhosis or advanced chronic liver disease, and mean diameter of HCC; </p> </li> <li> <p>index test with predefined positivity criteria;</p> </li> <li> <p>type of contrast media used;</p> </li> <li> <p>reference standard tests;</p> </li> <li> <p>numbers of true positive, true negative, false positive, and false negative findings. We extracted these data for the two target conditions (HCC of any size and stage and resectable HCC); </p> </li> <li> <p>number of uninterpretable results;</p> </li> <li> <p>number of examinations not performed due to contraindications to MRI;</p> </li> <li> <p>possible conflict of interest of study authors.</p> </li> </ul> </p> <p>We summarised the data from each study in 2 × 2 tables (true positive; false positive; false negative; true negative), according to the index test considered, and we entered the data into Review Manager 5 (<a href="./references#CD014798-bbs2-0207" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <section id="CD014798-sec-0038"> <h5 class="title">Missing data</h5> <p>In the process of full‐text study retrieval, we used available sources to retrieve the relevant studies. When full‐text studies were not available, we contacted the primary authors directly by email to request the studies or data in question. </p> <p>We contacted primary authors by email to request missing data that were needed to design the 2 × 2 tables. If we received no reply, we sent a second e‐mail after two weeks. If no reply was received, we excluded the study in question. We reported on how many studies we had excluded for this reason. </p> </section> </section> <section id="CD014798-sec-0039"> <h4 class="title">Assessment of methodological quality</h4> <p>Two review authors (VG and TN) independently assessed the risk of bias of included studies and applicability of their results using QUADAS‐2 (revised tool for quality assessment of diagnostic accuracy studies) (<a href="./appendices#CD014798-sec-0081">Appendix 2</a>; <a href="./references#CD014798-bbs2-0223" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529-36.">Whiting 2011</a>). In cases of disagreement, we reached consensus through discussion. We addressed aspects of study quality involving the participant spectrum, index tests, target conditions, reference standards, and flow and timing. If some participants were not included in the analyses, we considered the study at high risk of bias. We classified a study at high risk of bias if at least one of the QUADAS‐2 domains was judged at high risk. </p> <p>We defined a time interval between the index test and the reference standard of three months as appropriate. According to a recent systematic review, the approximate HCC volume doubling time is four months to five months with significant range of 2.2 months to 11.3 months (<a href="./references#CD014798-bbs2-0197" title="NathaniP , GopalP , RichN , YoppA , YokooT , JohnB , et al.Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut2021;70(2):401-7.">Nathani 2021</a>). In accordance with suggestions from a previous systematic review, which noted the acceptable time interval being from one month to three months (<a href="./references#CD014798-bbs2-0170" title="KimSH , ChoiBI , LeeJY , KimSJ , SoYH , EunHW , et al.Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology2008;51(Suppl 1):52-60.">Kim 2008</a>), we assumed 90 days to be the most acceptable threshold. </p> </section> <section id="CD014798-sec-0040"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We carried out statistical analyses according to recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD014798-bbs2-0144" title="DeeksJJ , BossuytPM , LeeflangM , TakwoingiY , FlemyngE , MellorL .Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. London: Cochrane. Available from training.cochrane.org/handbook-diagnostic-test-accuracy/PDF/v2.">DTA Handbook 2021</a>). We performed a graphical descriptive analysis of the included studies. We reported forest plots (sensitivity and specificity separately, with their 95% confidence intervals (CIs)) and we provided a graphical representation of studies in the receiver operating characteristic (ROC) space (sensitivity against 1 – specificity) and then, we performed a meta‐analysis using the bivariate model and provided estimates of summary sensitivity and specificity. We used the pooled estimates obtained from the fitted models to calculate summary estimates of positive (LR+) and negative (LR–) likelihood ratios. We performed all statistical analyses using SAS statistical software, version 9.4 (SAS Institute Inc, Cary, NC, USA) and macro METADAS (<a href="./references#CD014798-bbs2-0144" title="DeeksJJ , BossuytPM , LeeflangM , TakwoingiY , FlemyngE , MellorL .Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. London: Cochrane. Available from training.cochrane.org/handbook-diagnostic-test-accuracy/PDF/v2.">DTA Handbook 2021</a>). </p> </section> <section id="CD014798-sec-0041"> <h4 class="title">Investigations of heterogeneity</h4> <p>We investigated the effects of the following sources of heterogeneity and rationale for our choice: </p> <p> <ul id="CD014798-list-0008"> <li> <p>study date (studies before compared to after the year 2011);</p> </li> <li> <p>inclusion of participants without cirrhosis: studies including 10% or more participants without cirrhosis compared to studies including less than 10% participants without cirrhosis; </p> </li> <li> <p>differences in prior tests: studies including participants who underwent US with or without AFP compared to studies with participants who underwent CT or CEUS; </p> </li> <li> <p>study location (population differences): studies conducted in the North and South America compared to Europe compared to Asia compared to Africa; </p> </li> <li> <p>participant selection: participants recruited from planned screening programmes compared to clinical cohorts; </p> </li> <li> <p>different HCC stage: studies with 20% or greater of resectable HCC compared to studies with less than 20% of resectable HCC; </p> </li> <li> <p>different reference standard: histology of the explanted liver compared to liver biopsy compared to another reference standard; </p> </li> <li> <p>different liver cirrhosis aetiology: studies including more than 80% of participants with hepatitis C or hepatitis B virus‐associated cirrhosis compared to studies including more than 20% of participants with non‐viral cirrhosis; </p> </li> <li> <p>studies with clear predefined MR positivity criteria compared to studies without predefined MR positivity criteria; </p> </li> <li> <p>studies using LI‐RADS as MR positivity criteria compared to studies using other definitions of positivity criteria; </p> </li> <li> <p>studies using LI‐RADS 5 only as MR positivity criteria compared to studies using LI‐RADS 4 and 5 as positivity criteria; </p> </li> <li> <p>type of contrast media used;</p> </li> <li> <p>studies with radiologists (defined experts in MRI technique) compared to studies without any definition of operator's expertise. </p> </li> </ul> </p> <p>We chose the above listed variables for the following reasons. Due to advancements in technology and change in diagnostic criteria, we considered the date of study publication. Searching the relevant literature, the earliest study on the accuracy of MRI for the diagnosis of HCC was published in 1998 (<a href="./references#CD014798-bbs2-0165" title="HoriM , MurakamiT , OiH , KimT , TakahashiS , MatsushitaM , et al.Sensitivity in detection of hypervascular hepatocellular carcinoma by helical CT with intra-arterial injection of contrast medium, and by helical CT and MR imaging with intravenous injection of contrast medium. Acta Radiologica1998;39(2):144-51.">Hori 1998</a>), and since then a significant number of studies have been published, reporting technological improvements. The LI‐RADS diagnostic criteria were first presented in 2011, with several updated versions published during the following years. The latest was published in 2018 (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>; <a href="./references#CD014798-bbs2-0149" title="ElsayesKM , KielarAZ , ChernyakV , MorshidA , FurlanA , MaschWR , et al.LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. Journal of Hepatocellular Carcinoma2019;6:49-69.">Elsayes 2019</a>). We chose 2011 as a cut‐off value, separating studies published before and after the first LI‐RADS criteria. The proportion of participants without cirrhosis is relevant because HCC in the absence of cirrhosis has different MRI characteristics. In epidemiological studies, this proportion is usually less than 10% (<a href="./references#CD014798-bbs2-0186" title="LokAS , SeeffLB , MorganTR , di BisceglieAM , SterlingRK , CurtoTM , et al.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology2009;136(1):138-48.">Lok 2009</a>; <a href="./references#CD014798-bbs2-0155" title="FornerA , ReigM , BruixJ .Hepatocellular carcinoma. Lancet2018;391(10127):1301-14.">Forner 2018a</a>). Inclusion of participants who underwent US as the only prior test as opposed to those who underwent CT or CEUS, which might produce differences in MRI accuracy estimates secondary to this different selection. There are differences in epidemiology, and clinical and radiological characteristics of HCC in Asia when compared to Western countries and also Africa. Differences in clinical and radiological characteristics are also expected according to the selection of study participants: surveillance programme or clinical setting. The proportion of resectable HCC found in the studies reflect different epidemiology and participant selection. The accuracy of MRI may vary according to the different reference standard, the type of contrast used, and the definition of positivity criteria. Different type of contrast media and operator's expertise may explain differences in interpretation of images. </p> <p>We estimated effects by adding covariates to the bivariate models. We assessed the statistical significance of the covariate effect on sensitivity and specificity using the log‐LR test for comparison of models with and without the covariate term. We considered P less than 0.05 as two‐sided and statistically significant. </p> </section> <section id="CD014798-sec-0042"> <h4 class="title">Sensitivity analyses</h4> <p>We assessed effects of risk of bias of included studies on diagnostic accuracy by performing a sensitivity analysis in which we excluded studies classified at high risk of bias in at least one of the domains of QUADAS‐2 (<a href="./appendices#CD014798-sec-0081">Appendix 2</a>). In addition, we defined the following signalling questions as most relevant, and we conducted a sensitivity analyses in which we excluded studies with answers of 'no' or 'unclear'. </p> <p> <ul id="CD014798-list-0009"> <li> <p>Were the positivity criteria defined?</p> </li> <li> <p>Were the reference standard results interpreted without the knowledge of the results of the index test? </p> </li> </ul> </p> <p>We planned to conduct sensitivity analyses in which we excluded studies published only in abstract or letter form. </p> </section> <section id="CD014798-sec-0043"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not plan to test for publication bias due to the lack of validated methods for diagnostic test accuracy reviews. </p> </section> <section id="CD014798-sec-0044"> <h4 class="title">Summary of findings</h4> <p>We prepared summary of findings tables to present the main results and key information regarding the certainty of evidence assessed using the GRADE approach (<a href="./references#CD014798-bbs2-0119" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al.GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>; <a href="./references#CD014798-bbs2-0212" title="SchünemannHJ , MustafaRA , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al.GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology2020;122:129-41.">Schünemann 2020a</a>; <a href="./references#CD014798-bbs2-0213" title="SchünemannHJ , MustafaRA , BrozekJ , SteingartKR , LeeflangM , MuradMH , et al.GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2020;122:142-52.">Schünemann 2020b</a>). As recommended, we rated the certainty of evidence as high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the certainty of evidence starts as high when there are high‐quality observational studies (cross‐sectional or cohort studies) that enrolled participants with diagnostic uncertainty. When we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels) and recorded them in the footnotes. </p> <p>We applied the GRADE judgements for the GRADE domains as following.</p> <p> <ul id="CD014798-list-0010"> <li> <p>Risk of bias: we used QUADAS‐2 to assess risk of bias.</p> </li> <li> <p>Indirectness: we used QUADAS‐2 for concerns of applicability and looked for important differences between the populations studied (e.g. the spectrum of disease), the setting, and the index test. </p> </li> <li> <p>Inconsistency: we carried out prespecified analyses to investigate potential sources of heterogeneity and downgraded when we could not explain inconsistency in the accuracy estimates. </p> </li> <li> <p>Imprecision: we looked at the CIs of sensitivity and specificity estimates and at the unexplained heterogeneity of the results. </p> </li> <li> <p>Publication bias: we did not evaluate publication bias due to the lack of validated methods for diagnostic test accuracy reviews. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014798-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014798-sec-0045"></div> <section id="CD014798-sec-0046"> <h3 class="title" id="CD014798-sec-0046">Results of the search</h3> <p>We ran the searches on 24 February 2021, and reran them on 9 November 2021. We identified 14,423 records by searching the Cochrane Hepato‐Biliary Group Controlled Trials Register (46 records), the Cochrane Hepato‐Biliary Group Diagnostic Test of Accuracy Studies Register (8), the Cochrane Library (351), MEDLINE Ovid (3074), Embase Ovid (6749), LILACS (60), and Science Citation Index – Expanded with Conference Proceedings Citation Index – Science (4135). We retrieved three additional records through handsearching other sources. We identified 4765 duplicates and excluded them from further analysis. After reading the title and abstract, we excluded 9544 records, as they did not meet the inclusion criteria. We retrieved full texts of the remaining 117 records, and after reading the full texts, we excluded 83 studies for various reasons (see <a href="./references#CD014798-sec-0091" title="">Characteristics of excluded studies</a> table). Finally, we included in our review 34 records reporting data on 34 studies (<a href="#CD014798-fig-0002">Figure 2</a>), including 4841 participants (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). The three additional studies that were retrieved through handsearching were all included in the analysis (<a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>). We applied no language restrictions in the inclusion criteria, which resulted in retrieving full‐text articles of 17 studies published in non‐English languages, of which two were included in the final analysis (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>) after translation by a member of the review team (AC). Further information was requested by e‐mail regarding three studies, and replies were not received (<a href="./references#CD014798-bbs2-0110" title="UedaK , KitagawaK , KadoyaM , MatsuiO , TakashimaT , YamahanaT .Detection of hypervascular hepatocellular carcinoma by using spiral volumetric CT: comparison of US and MR imaging. Abdominal Imaging1995;20(6):547-54. ">Ueda 1995</a>; <a href="./references#CD014798-bbs2-0095" title="PuigJ , MartinJ , DonosoL , FalcoJ , RueM .Comparison between biphasic helical CT and dynamic gadolinium-enhanced MR in the detection and characterization of focal hepatic lesions in cirrhotic patients. Radiologia1997;39(9):617-23. ">Puig 1997</a>; <a href="./references#CD014798-bbs2-0102" title="SimonG , LinkTM , WörtlerK , DoebereinerF , Schulte-FrohlindeE , Daldrup-LinkH , et al.Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. European Radiology2005;15(5):895-903. ">Simon 2005</a>). No data were obtained through correspondence with investigators. </p> <div class="figure" id="CD014798-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram. Date of search 9 November 2021" data-id="CD014798-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. Date of search 9 November 2021</p> </div> </div> </div> <p>We reported the main characteristics of the 34 references in the <a href="./references#CD014798-sec-0090" title="">Characteristics of included studies</a> table. All references are reported as full‐text publications, except one, which was published in abstract form only (<a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>). The studies were conducted from 1998 to 2021. </p> </section> <section id="CD014798-sec-0047"> <h3 class="title">Methodological quality of included studies</h3> <p>We reported in detail results of the quality assessment of included studies in the <a href="./references#CD014798-sec-0090" title="">Characteristics of included studies</a> tables, and we summarised this information in <a href="#CD014798-fig-0003">Figure 3</a> and <a href="#CD014798-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD014798-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies." data-id="CD014798-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> </div> <div class="figure" id="CD014798-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD014798-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> </div> <section id="CD014798-sec-0048"> <h4 class="title">Participant selection</h4> <section id="CD014798-sec-0049"> <h5 class="title">Risk of bias</h5> <p>Eight studies were at low risk of bias regarding patient selection (<a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>). One study was judged unclear for this domain, since there were no data on the presence of exclusion criteria (<a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>). Twenty‐five were at high risk of bias due to exclusion criteria we considered inappropriate in the domain of population characteristics (<a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>), unavailable data (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>), or HCC features (<a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). </p> </section> <section id="CD014798-sec-0050"> <h5 class="title">Applicability</h5> <p>We judged 14 studies at low concern regarding applicability (<a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). The other 20 studies were judged at high concern because they included only participants with decompensated liver disease stage in waiting list for OLT (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>), participants with a defined HCC diameter (<a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>), participants with suspected enhancing mass (<a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>), participants with available MRI only (<a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>), or not all participants having chronic liver disease (<a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>). </p> </section> </section> <section id="CD014798-sec-0051"> <h4 class="title">Index test</h4> <section id="CD014798-sec-0052"> <h5 class="title">Risk of bias</h5> <p>We judged 30 studies regarding the index test at low risk of bias as they clearly predefined the MRI positivity criteria (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). One study was unclear for this domain due to unclear blinding to reference standard results (<a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>). Three studies were at high risk of bias due to undefined MRI positivity criteria (<a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>). </p> </section> <section id="CD014798-sec-0053"> <h5 class="title">Applicability</h5> <p>We judged 33 studies regarding the index test at low concern (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). We judged one study at high concern due to positivity criteria not being used in routine clinical practice (<a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>). </p> </section> </section> <section id="CD014798-sec-0054"> <h4 class="title">Reference standard</h4> <p>In 10 studies, the reference standard was the pathology of the explanted liver (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>). In four studies the reference standard was histology in all participants (<a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>), in six studies it was OLT in some participants and histology in others (<a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>). In 14 studies, the reference standard was the combination of following options: OLT, histology (either biopsy or resection), or follow‐up using US, CT, MRI, AFP, laboratory, and clinical data (<a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). </p> <section id="CD014798-sec-0055"> <h5 class="title">Risk of bias</h5> <p>We judged six studies regarding the reference standard at low risk of bias (<a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>), five studies at uncertain risk (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>), and 23 at high risk of bias (<a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). Main reasons for judging studies at high risk of bias included statements explaining that the reference standard results were interpreted with the knowledge of the results of the index test, and in cases of biopsy, the procedure is usually performed after reviewing all available preprocedural imaging data. Uncertain risk of bias was judged due to lack of detailed information regarding the reference standard. </p> </section> <section id="CD014798-sec-0056"> <h5 class="title">Applicability</h5> <p>We judged 18 studies regarding the reference standard at low concern (<a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). Sixteen studies were at high concern due to OLT being the only reference standard (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>), and use of other inappropriate reference standards (clinical and laboratory data, US, CEUS) (<a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>). </p> </section> </section> <section id="CD014798-sec-0057"> <h4 class="title">Flow and timing</h4> <section id="CD014798-sec-0058"> <h5 class="title">Risk of bias</h5> <p>We judged three studies at low risk of bias regarding flow and timing (<a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>). Thirty studies were at high risk due to: inappropriate time between index test and reference standard (greater than 90 days) (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>), not all participants underwent the same reference standard (<a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>), or participants missing in the final analysis with no explanation (<a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>). One study was at uncertain risk of bias due to lack of information on time interval between index test and reference standard (<a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>). Nine studies reported non‐evaluable results (<a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>). </p> </section> </section> <section id="CD014798-sec-0059"> <h4 class="title">Overall assessment</h4> <p>All included studies were at overall high risk of bias. We judged five studies at low concern for applicability (<a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>). </p> </section> </section> <section id="CD014798-sec-0060"> <h3 class="title" id="CD014798-sec-0060">Findings</h3> <p>Thirty‐four studies with 4841 participants provided data assessing MRI for the diagnosis of HCC. The median prevalence of the target disease was 56% (interquartile range 36% to 66%). </p> <p>Thirty‐two studies reported the prevalence of participants with hepatic cirrhosis, and in 25 of them the reported prevalence was 100%. Fourteen studies reported the Child‐Pugh classification with a median of 76% (interquartile range 57% to 79%) classified as Child‐Pugh class A. Twenty‐nine studies reported information on liver disease aetiology and a median of 68% (interquartile range 48% to 79%) had viral aetiology. Twenty‐six studies reported the proportion of participants with resectable HCC, among which 16 reported all participants to have resectable HCC. Twenty‐three studies reported the mean diameter of the lesions with a median of 23 mm (interquartile range 18 mm to 32 mm). The studies were conducted from 1998 to 2021. </p> <p>Regarding study location, 15 studies were conducted in Europe, 11 in North America, and eight in Asia. Twenty studies were conducted in people with clinical suspicion of having HCC, six were conducted in the context of a surveillance programme, and eight performed MRI as a confirmatory test after a surveillance programme. Fourteen studies reported the number of uninterpretable index test results (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>; <a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>), ranging from 0/407 to 19/141. Two studies reported the number of examinations not performed due to contraindications. <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a> reported 23/294 participants and <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a> reported 2/55 participants. </p> <p>Seventeen studies reported no information about authors' possible conflict of interest (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002;</a><a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003;</a><a href="./references#CD014798-bbs2-0022" title="MarreroJA , HussainHK , NghiemHV , UmarR , FontanaRJ , LokAS .Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplantation2005;11(3):281-9. ">Marrero 2005</a>; <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0026" title="SeçilM , ObuzF , AltayC , GencelO , IğciE , SağolO , et al.The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagnostic and Interventional Radiology (Ankara, Turkey)2008;14(4):200-4. ">Seçil 2008</a>; <a href="./references#CD014798-bbs2-0011" title="GolfieriR , MariniE , BazzocchiA , FuscoF , TrevisaniF , SamaC , et al.Small (&lt;or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT [Ruolo della RM a doppio contrasto rispetto alla TC multidetettore nelladiagnosi del piccolo epatocarcinoma (≤3 cm) su cirrosi]. Radiologia Medica2009;14(8):1239-66. ">Golfieri 2009</a>; <a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a><a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018;</a><a href="./references#CD014798-bbs2-0016" title="KimJS , LeeJK , BaekSY , YunHI .Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdominal Radiology2020;45(1):211-9. ">Kim 2020</a>; <a href="./references#CD014798-bbs2-0014" title="KhatriG , PedrosaI , AnanthakrishnanL , deLeonAD , FetzerDT , LeyendeckerJ , et al.Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging: JMRI2020;51(2):415-25. ">Khatri 2020</a>), 10 reported possible conflict of interest (<a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0020" title="MaiwaldB , LobsienD , KahnT , StumppP .Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?PLoS One2014;9(11):e111935. ">Maiwald 2014;</a><a href="./references#CD014798-bbs2-0021" title="MarksRM , RyanA , HebaER , TangA , WolfsonTJ , GamstAC , et al.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. American Journal of Roentgenology2015;204(3):527-35. ">Marks 2015</a>; <a href="./references#CD014798-bbs2-0001" title="BesaC , LewisS , PandharipandePV , ChhatwalJ , KamathA , CooperN , et al.Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology2017;42(1):179-90. ">Besa 2017</a>; <a href="./references#CD014798-bbs2-0015" title="KimSY , AnJ , LimYS , HanS , LeeJY , ByunJH , et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncology2017;3(4):456-63. ">Kim 2017</a>; <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>; <a href="./references#CD014798-bbs2-0031" title="Vietti VioliN , LewisS , LiaoJ , HulkowerM , Hernandez-MezaG , SmithK , et al.Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. European Radiology2020;30(11):6003-13. ">Vietti Violi 2020;</a><a href="./references#CD014798-bbs2-0005" title="DarnellA , RimolaJ , BelmonteE , RipollE , Garcia-Criado Á, CaparrozC , et al.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. European Radiology2021;31(7):4794-803. ">Darnell 2021</a>), and seven reported no possible conflict of interest (<a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0009" title="DumitrescuCI , GheoneaIA , SăndulescuL , SurlinV , SăftoiuA , DumitrescuD .Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. Medical Ultrasonography2013;15(4):261-7. ">Dumitrescu 2013</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0007" title="DemirtasCO , GunduzF , TuneyD , BaltaciogluF , KaniHT , BugdayciO , et al.Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. European Journal of Gastroenterology and Hepatology2020;32(4):517-23. ">Demirtas 2020</a>; <a href="./references#CD014798-bbs2-0033" title="WuY , HuangL , LiB , LiH .The diagnostic value of Gd-EOB-DTPA-enhanced MRI scans in small hepatocellular carcinoma in patients with liver cirrhosis. International Journal of Clinical and Experimental Medicine2020;13(9):6909-15. ">Wu 2020</a>). </p> <p>Among the 10 studies with the pathology of explanted liver as the reference standard, four studies reported no alternative diagnosis in participants without HCC (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>). <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a> reported eight dysplastic nodules and six macroregenerative nodules in 13 participants without HCC; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a> reported one haemangioma and one focal nodular hyperplasia in 14 participants without HCC; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a> reported three focal areas of fibrosis, three vessels and three benign regenerative nodules in 23 participants without HCC; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a> reported six dysplastic or regenerative macronodules, two haemangiomas and one focal infarct in 99 participants without HCC; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a> reported 15 dysplastic nodules and three large regenerative nodules in 11 participants without HCC; and <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a> reported six cholangiocarcinomas, two haemangiomas, and six dysplastic nodules in 164 participants without HCC. </p> <p>In the four studies with histology of biopsied focal lesions in all participants as the reference standard <a href="./references#CD014798-bbs2-0010" title="GiorgioA , De StefanoG , CoppolaC , FerraioliG , EspositoV , Di SarnoA , et al.Contrast-enhanced sonography in the characterization of small hepatocellular carcinomas in cirrhotic patients: comparison with contrast-enhanced ultrafast magnetic resonance imaging. Anticancer Research2007;27(6C):4263-9. ">Giorgio 2007</a> reported eight regenerative nodules, four dysplastic nodules, six areas of focal steatosis, four haemangiomas, one metastasis, one non‐Hodgkin's lymphoma, and one focal nodular hyperplasia in 25 participants without HCC; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a> reported two cholangiocarcinomas, three low‐grade dysplastic nodules, and 18 macroregenerative nodules in 22 participants without HCC; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a> reported seven dysplastic nodules, nine macroregenerative nodules, one cholangiocarcinoma, one epithelioid haemangioendothelioma, and nine areas of chronic liver disease in 27 participants without HCC; and <a href="./references#CD014798-bbs2-0028" title="ShinSK , KimYS , ChoiSJ , ShimYS , JungDH , KwonOS , et al.Characterization of small (≤ 3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: a STARD-compliant article. Medicine2017;96(29):e7278. ">Shin 2017</a> reported one dysplastic nodule in 18 participants without HCC. </p> <p><a href="#CD014798-fig-0005">Figure 5</a> shows a graphical representation of studies in the ROC space (sensitivity against 1 – specificity) and <a href="#CD014798-fig-0006">Figure 6</a> shows a forest plot of sensitivity and specificity with their 95% CIs. For the 34 studies, the reported sensitivity ranged from 44% to 96% and the specificity ranged from 33% to 100%. </p> <div class="figure" id="CD014798-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Summary receiver operating characteristic (ROC) comparing magnetic resonance imaging (MRI) and different reference standards in 34 studies. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, using periodic testing with ultrasound, alpha‐fetoprotein, computed tomography or MRI." data-id="CD014798-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing magnetic resonance imaging (MRI) and different reference standards in 34 studies. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, using periodic testing with ultrasound, alpha‐fetoprotein, computed tomography or MRI. </p> </div> </div> </div> <div class="figure" id="CD014798-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of hepatocellular carcinoma of any size and stage against different reference standards in 34 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months.Values between square brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD014798-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of hepatocellular carcinoma of any size and stage against different reference standards in 34 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months. </p> <p>Values between square brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> <p>CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <p>We performed a meta‐analysis of all 34 included studies using the bivariate model, and we obtained the following pooled estimates: sensitivity 84.4% (95% CI 80.1% to 87.9%); specificity 93.8% (95% CI 90.1% to 96.1%); LR+ 13.5 (95% CI 8.5 to 21.7); and LR– 0.17 (95% CI 0.13 to 0.21). </p> <p><a href="#CD014798-tbl-0003">Table 1</a> shows post‐test probabilities calculated using pooled LRs, according to three different pre‐test probabilities, the median and interquartile range of HCC prevalence derived from our study analysis. </p> <div class="table" id="CD014798-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post‐test probabilities</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Pre‐test</b> <b>probability</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Likelihood ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Post‐test probability</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MRI: magnetic resonance imaging</p> <p><sup>a</sup>Positive likelihood ratio.<br/><sup>b</sup>Negative likelihood ratio. </p> </div> </div> <p>We assessed the diagnostic accuracy for resectable HCC as a secondary objective. We found 16 studies including all participants with resectable HCC (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0006" title="deLédinghenV , LaharieD , LecesneR , Le BailB , WinnockM , BernardPH , et al.Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European Journal of Gastroenterology and Hepatology2002;14(2):159-65. ">de Lédinghen 2002</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0002" title="BhartiaB , WardJ , GuthrieJA , RobinsonPJ .Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. American Journal of Roentgenology2003;180(3):577-84. ">Bhartia 2003</a>; <a href="./references#CD014798-bbs2-0017" title="LauensteinTC , SalmanK , MorreiraR , HeffronT , SpiveyJR , MartinezE , et al.Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. American Journal of Roentgenology2007;189(3):663-70. ">Lauenstein 2007</a>; <a href="./references#CD014798-bbs2-0012" title="HannaRF , KasedN , KwanSW , GamstAC , SantosaAC , HassaneinT , et al.Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. American Journal of Roentgenology2008;190(1):47-57. ">Hanna 2008</a>; <a href="./references#CD014798-bbs2-0025" title="SangiovanniA , ManiniMA , IavaroneM , RomeoR , ForzenigoLV , FraquelliM , et al.The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut2010;59(5):638-44. ">Sangiovanni 2010</a>; <a href="./references#CD014798-bbs2-0034" title="YuNC , ChaudhariV , RamanSS , LassmanC , TongMJ , BusuttilRW , et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical Gastroenterology and Hepatology2011;9(2):161-7. ">Yu 2011</a>; <a href="./references#CD014798-bbs2-0027" title="SerstéT , BarrauV , OzenneV , VulliermeMP , BedossaP , FargesO , et al.Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology2012;55(3):800-6. ">Sersté 2012</a>; <a href="./references#CD014798-bbs2-0013" title="HwangJ , KimYK , KimJM , LeeWJ , ChoiD , HongSS .Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transplantation2014;20(12):1436-46. ">Hwang 2014</a>; <a href="./references#CD014798-bbs2-0019" title="LinMT , WangCC , ChengYF , EngHL , YenYH , TsaiMC , et al.Comprehensive comparison of multiple-detector computed tomography and dynamic magnetic resonance imaging in the diagnosis of hepatocellular carcinoma with varying degrees of fibrosis. PLoS One2016;11(11):e0166157. ">Lin 2016</a>; <a href="./references#CD014798-bbs2-0032" title="Villacastín RuizE , Caro-Patón GómezA , Calero AguilarH , Pérez SaboridoB , García PajaresF , Sánchez AntolínG , et al.Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. European Journal of Gastroenterology and Hepatology2016;28(4):412-20. ">Villacastin Ruiz 2016</a>; <a href="./references#CD014798-bbs2-0029" title="SutherlandT , WattsJ , RyanM , GalvinA , TempleF , VuongJ , et al.Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. Journal of Medical Imaging and Radiation Oncology2017;61(1):34-9. ">Sutherland 2017</a>; <a href="./references#CD014798-bbs2-0023" title="McNamaraMM , ThomasJV , AlexanderLF , LittleMD , BolusDN , LiYE , et al.Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data – a pilot study. Abdominal Radiology2018;43(10):2686-92. ">McNamara 2018</a>; <a href="./references#CD014798-bbs2-0024" title="MinJH , KimYK , SinnDH , ChoiSY , JeongWK , LeeWJ , et al.Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. Abdominal Radiology2018;43(9):2309-20. ">Min 2018a</a>; <a href="./references#CD014798-bbs2-0004" title="BrunsingRL , ChenDH , SchleinA , WolfsonT , GamstA , MamidipalliA , et al.Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiology. Imaging Cancer2019;1(2):e190010. ">Brunsing 2019</a>). We performed a meta‐analysis and obtained the following estimates: sensitivity 84.3% (95% CI 77.6% to 89.3%); specificity 92.9% (95% CI 88.3% to 95.9%); LR+ 11.9 (95% CI 7.0 to 20.2); and LR– 0.17 (95% CI 0.12 to 0.25). <a href="#CD014798-fig-0007">Figure 7</a> shows the forest plot of sensitivity and specificity with their 95% CIs. </p> <div class="figure" id="CD014798-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of resectable hepatocellular carcinoma against different reference standards in 16 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months.Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD014798-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of resectable hepatocellular carcinoma against different reference standards in 16 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months. </p> <p>Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> <p>CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> </div> <section id="CD014798-sec-0061"> <h4 class="title">Heterogeneity analysis</h4> <p>We investigated heterogeneity for all the predefined potential sources (<a href="#CD014798-sec-0023">Secondary objectives</a>). <a href="#CD014798-tbl-0004">Table 2</a> shows the comparisons of the different predefined subgroups. The prevalence of viral aetiology may in part explain the inconsistency of the overall results. In fact, studies which included less than 80% of participants with viral aetiology showed a higher sensitivity (87.6%, 95% CI 83.8% to 90.7% compared to 74.9%, 95% CI 64.4% to 83.1%) and a lower specificity (94.5%, 95% CI 90.7% to 96.8% compared to 96.5%, 95% CI 68.6% to 99.7%) than studies which included greater than 80% of participants with viral aetiology. Another possible source of heterogeneity was the study setting (clinical setting, confirmatory test after screening, or initial screening test). The sensitivity was lowest in the setting of confirmatory test after screening (77.1%, 95% CI 63.7% to 86.6% compared to 85.0%, 95% CI 78.0% to 90.1% in clinical setting and 86.8%, 95% CI 82.9% to 90.0% in initial screening), while specificity was the highest in initial screening test setting (96.2%, 95% CI 92.2% to 98.2% compared to 91.7%, 95% CI 75.1% to 97.6% in clinical setting and 93.3% 95% CI 88.1% to 96.3% in the setting of confirmatory test after screening). The comparison of the other subgroups assessing the possible role of study date and location, inclusion of participants without cirrhosis, the proportion of included participants with resectable HCC, the use of different contrast media, and the use of different reference standard did not show any differences. </p> <div class="table" id="CD014798-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for magnetic resonance imaging</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Specificity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (80.1 to 87.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8 (90.1 to 96.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Sensitivity analyses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary outcome (resectability 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3 (77.6 to 89.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.9 (88.3 to 95.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positivity criteria clearly defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.9 (79.3 to 87.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8 (89.9 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference standard blinded</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.8 (66.4 to 84.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.3 (81.5 to 94.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="24" valign="top"> <p><b>Subgroups analyses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Publication year</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published before 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.4 (72.8 to 89.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.3 (80.6 to 96.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.621</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published after 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.2 (80.2 to 89.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.6 (90.9 to 96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of cirrhosis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cirrhosis &gt; 90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.9 (78.7 to 88.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.3 (89.4 to 95.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.745</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cirrhosis &lt; 90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.8 (80.1 to 93.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8 (85.7 to 99.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Study location</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.9 (73.0 to 88.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (85.6 to 96.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.833</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.1 (82.5 to 90.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.4 (89.5 to 98.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (78.5 to 89.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.3 (83.7 to 96.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Setting</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting clinical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (82.9 to 90.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.3 (88.1 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting confirmatory test after screening</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.1 (63.7 to 86.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.7 (75.1 to 97.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting initial screening test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.0 (78.0 to 90.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.2 (92.2 to 98.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of resectable HCC</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.7 (82.6 to 89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (70.4 to 95.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.593</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.4 (79.5 to 89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.6 (88.8 to 96.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><i>Reference standard</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.5 (62.8 to 88.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.2 (85.3 to 97.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.620</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.6 (83.7 to 92.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.4 (87.0 to 96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT and histology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.1 (76.1 to 83.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.9 (53.4 to 97.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mix</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.0 (77.8 to 91.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.2 (90.9 to 97.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of viral aetiology</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral &lt; 80%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (83.8 to 90.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.5 (90.7 to 96.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral &gt; 80%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9 (64.4 to 83.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5 (68.6 to 99.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>LI‐RADS positivity criteria</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LI‐RADS positivity criteria not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (79.9 to 88.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (88.7 to 95.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.829</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LI‐RADS positivity criteria used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.7 (67.3 to 92.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.3 (88.2 to 98.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Type of contrast media</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gd extracellular + SPIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.2 (80.1 to 90.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (87.7 to 96.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.793</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gd intracellular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 (74.4 to 88.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.5 (88.0 to 98.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Operator expertise</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Operator expertise reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (55.2 to 88.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.4 (85.3 to 98.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Operator expertise not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.2 (80.9 to 88.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.9 (89.8 to 96.4)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; Gd: gadolinium; HCC: hepatocellular carcinoma; LI‐RADS: Liver Imaging Reporting and Data System criteria; OLT: orthotopic liver transplantation; SPIO: superparamagnetic iron oxide. </p> </div> </div> </section> <section id="CD014798-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>When considering the 31 studies that clearly prespecified the positivity criteria, we obtained a pooled sensitivity of 83.9% (95% CI 79.3% to 87.5%) and a specificity of 93.8% (95% CI 89.9% to 96.3%) (<a href="#CD014798-tbl-0004">Table 2</a>). </p> <p>When considering only the seven studies in which the reference standard results were interpreted without the knowledge of the results of the index test, we obtained a pooled sensitivity of 76.8% (95% CI 66.4% to 84.7%) and a specificity of 89.3% (95% CI 81.5% to 94.0%) (<a href="#CD014798-tbl-0004">Table 2</a>). </p> <p>We did not perform the planned sensitivity analysis in which studies published only in abstract or letter form were excluded because only one study was published in abstract form (<a href="./references#CD014798-bbs2-0008" title="Di CarloI , LoriaF , LoriaG , BasileS , RandazzoD , FrosinaL , et al.Diagnosis of small hepatic nodules in cirrhotic liver: role of contrast-enhanced ultrasound and contrast enhanced magnetic resonance imaging in the validation of the non invasive diagnostic criteria for hepato-cellular carcinoma. HPB : the Official Journal of the International Hepato Pancreato Biliary Association2012;14(Suppl 2):435. ">Di Carlo 2012</a>). All other included studies were published as full‐text articles. </p> <p>We did not perform the planned sensitivity analysis in which studies at high risk of bias were excluded as all the included studies were judged at high risk of bias. </p> </section> <section id="CD014798-sec-0063"> <h4 class="title">Summary of findings tables</h4> <p>The main results are shown in the <a href="./full#CD014798-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD014798-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014798-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014798-sec-0064"></div> <section id="CD014798-sec-0065"> <h3 class="title" id="CD014798-sec-0065">Summary of main results</h3> <p>The aim of this review was to assess the diagnostic accuracy of MRI for the diagnosis of HCC of any size and at any stage in adults with chronic liver disease. We included 34 studies that assessed 4841 participants, 20 were conducted in people with clinical suspicion of having HCC, six were conducted in the context of a surveillance programme, and eight performed MRI as a confirmatory test after a surveillance programme. The main results are presented in <a href="./full#CD014798-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD014798-tbl-0002">summary of findings Table 2</a>. </p> <p>For the 34 included studies, we performed a meta‐analysis using the bivariate model, and we obtained the following pooled estimates: sensitivity 84.4% (95% CI 80.1% to 87.9%) and specificity 93.8% (95% CI 90.1% to 96.1%) for the diagnosis of HCC at any size and stage (primary outcome). In <a href="#CD014798-tbl-0003">Table 1</a>, we showed the post‐test probability of having HCC in the case of positive or negative result of the index test, assuming different values of pretest probability. </p> <p>Sixteen studies included only participants with HCC amenable for surgical resection, and the pooled estimate of sensitivity was 84.3% (95% CI 77.6% to 89.3%) and specificity 92.9% (95% CI 88.3% to 95.9%) for the diagnosis of resectable HCC (secondary outcome). </p> <p>We judged all included studies at high risk of bias in at least one domain, and we assessed the results of 29/34 studies to be at high concern for applicability. </p> <p>We summarised these main results of analyses in <a href="./full#CD014798-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD014798-tbl-0002">summary of findings Table 2</a>, assuming three different prevalence values (36%, 56%, and 66%). The prevalence of HCC varied widely in all included studies, from 3% to 90%, according to the study design and different settings. For exemplification, we considered three values of HCC prevalence: 36% for a population with low clinical suspicion, 56% as a median derived from our study analysis, and 66% for a population with high clinical suspicion. These values represent the median and interquartile range of HCC prevalence derived from our study analysis. </p> <p>For participants with HCC at any size and stage, we assumed the following consequences of test results: people with true‐positive results, that is, those with HCC and positive test results, will receive the appropriate treatment (surgery, local ablative therapy, or systemic chemotherapy); people with true‐negative results, that is, those without HCC and negative test results, will not undergo inappropriate treatment or unnecessary further testing; people with false‐negative results, that is, those with HCC and negative test results, will be misdiagnosed, not receive the appropriate treatment, and might be detected later with more severe HCC; people with false‐positive results, that is, those without HCC and positive test results, will undergo further testing and possibly an inappropriate treatment. </p> <p>Considering a hypothetical cohort of 1000 people with HCC prevalence of 56% (the median value in the included studies), we can expect 87 false‐negative and 27 false‐positive results; with a lower prevalence of 36%, we can expect 56 false‐negative and 40 false‐positive results, and with a higher prevalence of 66%, we can expect 103 false‐negative and 21 false‐positive results. We judged the certainty of evidence to be low, downgrading two levels due to high risk of bias and indirectness. </p> <p>For participants with resectable HCC, considering a hypothetical cohort of 1000 people with HCC prevalence of 56%, we can expect 88 false‐negative and 31 false‐positive results; with a prevalence of 36%, we can expect 57 false‐negative and 45 false‐positive results; with a prevalence of 66%, we can expect 104 false‐negative and 24 false‐positive results. We judged the certainty of evidence to be low, downgrading two levels due to high risk of bias and indirectness. </p> </section> <section id="CD014798-sec-0066"> <h3 class="title" id="CD014798-sec-0066">Strengths and weaknesses of the review</h3> <p>This review included 34 studies, covering a time span of 23 years, from 1998 to 2021 and wide geographical areas, including areas with high and low prevalence of chronic liver disease and HCC. </p> <p>Fifteen studies were conducted in Europe, 11 in the USA, and eight in Asia. In terms of number of participants, studies performed in Asia included 1969 participants, the USA 1471 participants, and Europe 1401. We found no studies from Africa, where HCC is highly prevalent (<a href="./references#CD014798-bbs2-0153" title="FerlayJ , ColombetM , SoerjomataramI , MathersC , ParkinDM , PiñerosM , et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer2019;144(8):1941-53.">Ferlay 2019</a>). </p> <p>An overall quality assessment of the studies showed their methodological weaknesses. We judged all studies at high risk of bias mainly due to inappropriate exclusion criteria, unavailable data, reference standard results interpreted with knowledge of the index test (unavoidable in cases of biopsy), fact that not all participants underwent the same reference standard, and time interval between index test and reference standard being more than 90 days. The choice of reference standard represents a major concern for all studies, and we recognise none is perfect. Fourteen of 34 studies used as the reference standard the combination of OLT, histology (either biopsy or resection), or follow‐up using US, CT, MRI, AFP, laboratory, and clinical data. This choice, even if it reflects usual clinical practice, introduces an unavoidable different‐verification bias as the results of the index test influence the decision on which reference standard is used. In contrast, the most common single reference standard used in 10/34 studies, was the pathology of the explanted liver. It is the most accurate reference standard, allowing the histological evaluation of the whole liver in all participants. However, this almost perfect reference standard is feasible only in studies conducted on participants with advanced and decompensated liver diseases on a waiting list for transplantation, that do not represent the intended spectrum of liver disease severity. In fact, the aim of the present review was to assess MRI accuracy in participants with the whole spectrum of liver disease severity without any exclusion for severity of liver disease or HCC volume. Accordingly, correct estimates of MRI accuracy can be obtained only at the expense of their applicability. In 4/34 studies, the reference standard was histology in all participants avoiding a different‐verification bias but preventing blinding to the results of the index test as biopsy is usually performed after reviewing all the available preprocedural imaging data with a consequent high risk of bias. </p> <p>We judged 14 studies in which the time interval between the index test and reference standard was longer than 90 days to be at high risk of bias. In fact, in diagnostic test accuracy assessment, it is necessary to have the time interval between index test and reference standard as short as possible (<a href="./references#CD014798-bbs2-0139" title="ColliA , FraquelliM , CasazzaG , ConteD , NikolovaD , DucaP , et al.The architecture of diagnostic research: from bench to bedside – research guidelines using liver stiffness as an example. Hepatology2014;60(1):408-18.">Colli 2014</a>). Longer time intervals impair accurate assessment due to possible changes in lesion size and morphological features during certain periods of time. According to the latest systematic review, the approximate HCC volume doubling time is four to five months, with significant range of 2.2 months to 11.3 months (<a href="./references#CD014798-bbs2-0197" title="NathaniP , GopalP , RichN , YoppA , YokooT , JohnB , et al.Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut2021;70(2):401-7.">Nathani 2021</a>). In accordance with suggestions from a previous systematic review that noted the acceptable time interval being from one to three months (<a href="./references#CD014798-bbs2-0170" title="KimSH , ChoiBI , LeeJY , KimSJ , SoYH , EunHW , et al.Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology2008;51(Suppl 1):52-60.">Kim 2008</a>), we assumed 90 days to be the most acceptable threshold. </p> <p>We found two studies reporting the number of examinations not performed due to contraindications (7.8% and 3.6%), and 14 studies reporting the number of uninterpretable index test results (ranging from 0% to 13%). In the process of visual interpretation of MRI examinations, sometimes it is impossible for the radiologist to make a definite diagnosis of HCC. This is primarily due to unclear visual representation and absence of morphological criteria needed for a definite diagnosis (non‐rim‐like hyperenhancement, non‐peripheral washout in portal‐venous and subsequent phases, enhancing capsule, etc.) (<a href="./references#CD014798-bbs2-0180" title="American College of Radiology.Liver imaging reporting and data system, 2018. www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf (accessed 10 July 2020).">LI‐RADS 2018</a>). Technical aspects of an MRI examination such as participant movement and breath‐hold, scanning protocol, application of adequate type and amount of contrast, and acquisition of correct phases and sequences (arterial, portal‐venous, late phase) can impair liver imaging and its correct interpretation. All the studies that reported some uninterpretable results excluded these results from analyses preventing an assessment of their effect on the accuracy estimates. </p> <p>Using QUADAS‐2, we judged 29/34 studies at high concern for applicability mainly due to the selective inclusion of participants with decompensated advanced liver disease or a definite HCC diameter, and the use of pathological examination of the whole liver as the reference standard. </p> <p>Not all studies reported on all covariates that we planned to assess as a possible source of heterogeneity, and this might have impaired the analyses. Most information on MELD (Model for End‐Stage Liver Disease) and Child‐Pugh class A stage in the studies was missing. </p> <section id="CD014798-sec-0067"> <h4 class="title">Strengths and weaknesses of the review process</h4> <section id="CD014798-sec-0068"> <h5 class="title">Search strategy</h5> <p>Our search strategy provided a significant number of studies performed in various geographical areas with high and low prevalence of chronic liver disease and HCC. Manually searching the references of the included studies and previous narrative and systematic reviews identified three additional studies, which were included in the final analysis. We applied no language restrictions in the inclusion criteria, which resulted in retrieving full‐text articles of 17 studies published in non‐English languages, two of which we included in the final analysis. We requested further information from study authors regarding five studies, but they provided no information. We are confident that the search strategy resulted in the detection of most eligible studies, with a low probability of undetected relevant studies. </p> </section> <section id="CD014798-sec-0069"> <h5 class="title">Quality assessment and data extraction</h5> <p>We consider our attempts to reduce subjectivity in our judgements to minimise errors and miscalculations in data extraction to be the strength of this review. Two review authors independently assessed the risk of bias of the included studies and applicability of their results using the QUADAS‐2 tool. We extracted data using a standardised and piloted data extraction form. In case of disagreement, we reached consensus through discussion. Disagreements were most frequent for the two QUADAS‐2 domains participant selection (10 studies), and reference standard (six studies). All agreements were reached through discussion between two review authors, and the conclusions were discussed and approved by a third review author. For data extraction, most of the discordances were due to miscalculations and typographical errors, which were easily resolved. The same review authors assessed the certainty of evidence using the GRADE approach and the level of agreement was high. </p> </section> <section id="CD014798-sec-0070"> <h5 class="title">Review analysis</h5> <p>We performed a meta‐analysis using the bivariate model, as the results of the index test were reported as dichotomous (positive or negative) with no explicit threshold. We recognise that implicit thresholds cannot be excluded. The pooled estimates of sensitivity ranged from 44% to 96% and those of specificity from 33% to 100%. </p> <p>Three studies included fewer than 30 participants and their results were quite imprecise with very wide CIs (<a href="./references#CD014798-bbs2-0003" title="BornM , LayerG , KreftB , SchwarzN , SchildH .MRI, CT and CT arterial portography in the diagnosis of malignant liver tumors in liver cirrhosis [MRT, CT und CTAP in der Diagnostik maligner Lebertumoren bei Leberzirrhose]. RöFo: Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin1998;168(6):567-72. ">Born 1998</a>; <a href="./references#CD014798-bbs2-0018" title="LibbrechtL , BielenD , VerslypeC , VanbeckevoortD , PirenneJ , NevensF , et al.Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplantation2002;8(9):749-61. ">Libbrecht 2002</a>; <a href="./references#CD014798-bbs2-0030" title="TeefeySA , HildeboldtCC , DehdashtiF , SiegelBA , PetersMG , HeikenJP , et al.Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology2003;226(2):533-42. ">Teefey 2003</a>; <a href="#CD014798-fig-0006">Figure 6</a>). </p> <p>Inconsistency of the overall results may in part be explained by the inclusion of participants with viral aetiology of chronic liver disease and study setting. Studies which included less than 80% of participants with viral aetiology showed a higher sensitivity and a lower specificity than studies which included more than 80% of participants with viral aetiology. Another possible source of heterogeneity was the study setting (clinical setting, confirmatory test after screening, or initial screening test). The sensitivity was lowest in the setting of confirmatory test after screening, while specificity was the highest in initial screening test setting. Moreover, different geographic areas, advancements in technology (studies published before and after the year 2011), severity of the underlying disease (prevalence of cirrhosis), difference in the choice of the reference standards, use of LI‐RADS positivity criteria, use of different contrast types, clear definition of positivity criteria, and operator expertise seem unable to explain the observed inconsistencies. Some of our planned investigations were not possible due to lack of data (MELD score, Child‐Pugh classification of severity of cirrhosis), and lack of published studies (comparison of studies using LI‐RADS 5 only as MR positivity criteria compared to studies using LI‐RADS 4 and 5 as positivity criteria, and comparison of studies including participants who underwent US with or without AFP compared to studies with participants who underwent CT or CEUS). </p> <p>Furthermore, we were able to investigate only characteristics that could be assessed at study level whereas participants' factors or HCC characteristics can only be assessed by aggregate statistics with the inherent risk of ecological bias (<a href="./references#CD014798-bbs2-0209" title="RobinsonWS .Ecological correlations and the behavior of individuals. American Sociological Review1950;15:351-7.">Robinson 1950</a>; <a href="./references#CD014798-bbs2-0206" title="ReadeMC , DelaneyA , BaileyMJ , AngusDC .Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis – funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. Critical Care2008;12(4):220.">Reade 2008</a>). Therefore, some important relationships, such as the one with HCC volume, could have been missed. In addition, many of the included studies did not report data on the covariates of interest. </p> <p>We excluded studies that reported only per‐lesion analyses and included only studies with per‐patient analyses. Per‐patient and per‐lesion analyses represent two different approaches to diagnostic accuracy assessment and their choice depends on the type of clinical or scientific question, and requires different and appropriate statistical methodology. In the present review, we aimed to assess the accuracy of MRI for the diagnosis HCC. Consequently, we chose to include studies that evaluated how MRI is able to detect people with HCC at any size and any stage, therefore we applied a per‐patient approach. Otherwise, per‐lesion analysis is properly used to assess accuracy in detecting multiple lesions on a single image, providing information that is relevant for HCC staging. Studies planning per‐lesion analysis require a different methodological approach and cannot be pooled with studies using a per‐patient approach (<a href="./references#CD014798-bbs2-0129" title="ChangKC , LeungCC , TamCM .Per lesion analysis is misleading. Thorax2006;61(4):364.">Chang 2006</a>; <a href="./references#CD014798-bbs2-0232" title="ZwindermanAH , GlasAS , BossuytPM , FlorieJ , BipatS , StokerJ .Statistical models for quantifying diagnostic accuracy with multiple lesions per patient. Biostatistics2008;9(3):513-22.">Zwinderman 2008</a>). Furthermore, the inclusion criteria of studies planning a per‐lesion analysis are quite different and do not match our review question. In fact, they usually do not include people with chronic liver disease and suspected HCC, but people with known focal liver lesions, encompassing HCCs, cholangiocarcinomas, benign liver tumours, and even metastases from abdominal or extra‐abdominal primary cancers. </p> <p>Most studies (31/34) reported a clear definition of diagnostic criteria and we tried to explore the effect on the diagnostic accuracy estimates of different criteria, traditional perfusion compared to LI‐RADS criteria. However, only 5/34 studies used LI‐RADS positivity criteria and we were unable to find a difference. </p> <p>We were also unable to estimate the effect of uninterpretable results as only 14 studies reported the frequency of technical failures that excluded these results from analysis. The exclusion of uninterpretable results could have produced an overestimation of the accuracy estimates (<a href="./references#CD014798-bbs2-0137" title="CohenJF , KorevaarDA , AltmanDG , BrunsDE , GatsonisCA , HooPL , et al.STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open2016;6:e012799.">Cohen 2016</a>). </p> <p>The sensitivity analysis shows that the obtained results are arguably robust with no variation, after including only studies that clearly prespecified the positivity criteria, and including only those in which the reference standard results were interpreted without the knowledge of the results of the index test. </p> </section> </section> <section id="CD014798-sec-0071"> <h4 class="title">Comparison with previous research</h4> <p>We found 21 non‐Cochrane systematic reviews or reviews that assessed the accuracy of MRI for detection of HCCs (<a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a>; <a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a>; <a href="./references#CD014798-bbs2-0181" title="LiuX , ZouL , LiuF , ZhouY , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One2013;8(8):e70896.">Liu 2013</a>; <a href="./references#CD014798-bbs2-0224" title="WuLM , XuJR , GuHY , HuaJ , ChenJ , ZhuJ , et al.Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?Digestive Diseases and Sciences2013;58(11):3313-25.">Wu 2013</a>; <a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a>; <a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a>; <a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>; <a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a>; <a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a>; <a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a>; <a href="./references#CD014798-bbs2-0176" title="LiYW , ChenZG , WangJC , ZhangZM .Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World Journal of Gastroenterology2015;21(14):4334-44.">Li 2015b</a>; <a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a>; <a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a>; <a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a>; <a href="./references#CD014798-bbs2-0182" title="LiuX , JiangH , ChenJ , ZhouY , HuangZ , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplantation2017;23(12):1505-18.">Liu 2017</a>; <a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a>; <a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a>; <a href="./references#CD014798-bbs2-0128" title="ChanMV , HuoYR , TrieuN , MitchelleA , GeorgeJ , HeE , et al.Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis – a potential surveillance tool?Clinical Gastroenterology and Hepatology2021;S1542-3565(21):00215-9.">Chan 2021</a>; <a href="./references#CD014798-bbs2-0151" title="FengZ , ZhaoH , GuanS , WangW , RongP .Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: a systematic review and meta-analysis. Liver International2021;41(5):1117-28.">Feng 2021</a>; <a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a>). </p> <p>Ten reviews assessed the accuracy of MRI alone (<a href="./references#CD014798-bbs2-0181" title="LiuX , ZouL , LiuF , ZhouY , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One2013;8(8):e70896.">Liu 2013</a>; <a href="./references#CD014798-bbs2-0224" title="WuLM , XuJR , GuHY , HuaJ , ChenJ , ZhuJ , et al.Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?Digestive Diseases and Sciences2013;58(11):3313-25.">Wu 2013</a>; <a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a>; <a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a>; <a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a>; <a href="./references#CD014798-bbs2-0176" title="LiYW , ChenZG , WangJC , ZhangZM .Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World Journal of Gastroenterology2015;21(14):4334-44.">Li 2015b</a>; <a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a>; <a href="./references#CD014798-bbs2-0128" title="ChanMV , HuoYR , TrieuN , MitchelleA , GeorgeJ , HeE , et al.Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis – a potential surveillance tool?Clinical Gastroenterology and Hepatology2021;S1542-3565(21):00215-9.">Chan 2021</a>; <a href="./references#CD014798-bbs2-0151" title="FengZ , ZhaoH , GuanS , WangW , RongP .Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: a systematic review and meta-analysis. Liver International2021;41(5):1117-28.">Feng 2021</a>; <a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a>); seven assessed the accuracy of CT and MRI (<a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a>; <a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a>; <a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a>; <a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a>; <a href="./references#CD014798-bbs2-0182" title="LiuX , JiangH , ChenJ , ZhouY , HuangZ , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplantation2017;23(12):1505-18.">Liu 2017</a>; <a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a>; <a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a>); one assessed US, CT, and MRI (<a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a>); one assessed US, CEUS, CT, and MRI (<a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>); one assessed CEUS, CT, and MRI (<a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a>); and one assessed AFP, US, CT, and MRI (<a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>). Due to differences in methodological approaches, inclusion and exclusion criteria, and in statistical analyses, these results are not comparable to each other neither to our present results. Six reviews performed per‐patient analysis, and the pooled sensitivity of MRI for the diagnosis of HCC in these reviews ranged from 80.6% to 91% and the specificity from 84.8% to 94% (<a href="#CD014798-tbl-0005">Table 3</a>) (<a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a>; <a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a>; <a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a>; <a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a>; <a href="./references#CD014798-bbs2-0128" title="ChanMV , HuoYR , TrieuN , MitchelleA , GeorgeJ , HeE , et al.Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis – a potential surveillance tool?Clinical Gastroenterology and Hepatology2021;S1542-3565(21):00215-9.">Chan 2021</a>; <a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a>). These results are in accordance with our present results, despite the methodological differences and the number of included studies. We additionally evaluated all the primary studies included in these systematic reviews and assessed them for inclusion in our analysis. </p> <div class="table" id="CD014798-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other systematic reviews on diagnostic accuracy of magnetic resonance imaging for hepatocellular carcinoma</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systematic</b> <b>review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> <b>type</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of included studies</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants analysed</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Specificity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Use of bivariate statistical model</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6 (70 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.8 (77 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (90 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (93 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (79 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (82 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (83 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (85 to 98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0128" title="ChanMV , HuoYR , TrieuN , MitchelleA , GeorgeJ , HeE , et al.Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis – a potential surveillance tool?Clinical Gastroenterology and Hepatology2021;S1542-3565(21):00215-9.">Chan 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1685</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (83.9 to 89.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.3 (87.3 to 92.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (84 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (91 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (82 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 (83 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (87 to 94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (93 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (89 to 94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (93 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0181" title="LiuX , ZouL , LiuF , ZhouY , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One2013;8(8):e70896.">Liu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (89 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (94 to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0224" title="WuLM , XuJR , GuHY , HuaJ , ChenJ , ZhuJ , et al.Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?Digestive Diseases and Sciences2013;58(11):3313-25.">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (77 to 97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (85 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>469</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (88 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (94 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83 (80 to 86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 (79 to 93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (74 to 83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (85 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (94 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0176" title="LiYW , ChenZG , WangJC , ZhangZM .Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World Journal of Gastroenterology2015;21(14):4334-44.">Li 2015b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (82 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (73 to 83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5 (73.1 to 79.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (76 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (92 to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1908</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (68 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (88 to 95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0182" title="LiuX , JiangH , ChenJ , ZhouY , HuangZ , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplantation2017;23(12):1505-18.">Liu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1735</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (90 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (87 to 91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82 (75 to 87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (82 to 95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (77 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (88 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0151" title="FengZ , ZhaoH , GuanS , WangW , RongP .Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: a systematic review and meta-analysis. Liver International2021;41(5):1117-28.">Feng 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (69 to 78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (77 to 98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77 (74 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> <p>Fifteen reviews performed per‐lesion analysis and the pooled sensitivity of MRI for detection of HCC ranged from 74% to 95%, and specificity from 78% to 96% (<a href="#CD014798-tbl-0005">Table 3</a>) (<a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a>; <a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a>; <a href="./references#CD014798-bbs2-0181" title="LiuX , ZouL , LiuF , ZhouY , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One2013;8(8):e70896.">Liu 2013</a>; <a href="./references#CD014798-bbs2-0224" title="WuLM , XuJR , GuHY , HuaJ , ChenJ , ZhuJ , et al.Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?Digestive Diseases and Sciences2013;58(11):3313-25.">Wu 2013</a>; <a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a>; <a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a>; <a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a>; <a href="./references#CD014798-bbs2-0176" title="LiYW , ChenZG , WangJC , ZhangZM .Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World Journal of Gastroenterology2015;21(14):4334-44.">Li 2015b</a>; <a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a>; <a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a>; <a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a>; <a href="./references#CD014798-bbs2-0182" title="LiuX , JiangH , ChenJ , ZhouY , HuangZ , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplantation2017;23(12):1505-18.">Liu 2017</a>; <a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a>; <a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a>; <a href="./references#CD014798-bbs2-0151" title="FengZ , ZhaoH , GuanS , WangW , RongP .Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: a systematic review and meta-analysis. Liver International2021;41(5):1117-28.">Feng 2021</a>). </p> </section> </section> <section id="CD014798-sec-0072"> <h3 class="title" id="CD014798-sec-0072">Applicability of findings to the review question</h3> <p>Using the QUADAS‐2 tool, we assessed the applicability of the results of the included studies. We judged only five studies to be at low concern for applicability, and we downgraded one level the certainty of evidence because of indirectness the other 29 studies. Twenty studies selected participants based on the diameter of the focal lesions or included only people from the waiting list for OLT excluding participants with less severe disease. In 16 studies, the choice of the pathology of the explanted liver as the reference standard also impaired the applicability of the results as this reference standard is applied exclusively to participants who had received a transplant. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014798-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of the diagnostic pathway for the diagnosis of hepatocellular carcinoma." data-id="CD014798-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of the diagnostic pathway for the diagnosis of hepatocellular carcinoma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. Date of search 9 November 2021" data-id="CD014798-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram. Date of search 9 November 2021</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies." data-id="CD014798-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study." data-id="CD014798-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Summary receiver operating characteristic (ROC) comparing magnetic resonance imaging (MRI) and different reference standards in 34 studies. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, using periodic testing with ultrasound, alpha‐fetoprotein, computed tomography or MRI." data-id="CD014798-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Summary receiver operating characteristic (ROC) comparing magnetic resonance imaging (MRI) and different reference standards in 34 studies. Reference standards were: the pathology of the explanted liver in case of transplantation; the histology of resected focal liver lesions, or the histology of biopsied focal liver lesion(s) with a follow‐up period of at least six months, using periodic testing with ultrasound, alpha‐fetoprotein, computed tomography or MRI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of hepatocellular carcinoma of any size and stage against different reference standards in 34 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months.Values between square brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD014798-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of hepatocellular carcinoma of any size and stage against different reference standards in 34 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months. </p> <p>Values between square brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> <p>CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of resectable hepatocellular carcinoma against different reference standards in 16 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months.Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive." data-id="CD014798-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plots of sensitivity and specificity of magnetic resonance imaging for detection of resectable hepatocellular carcinoma against different reference standards in 16 studies in alphabetical order. Reference standards were: the pathology of the explanted liver in case of transplantation, the histology of resected focal liver lesions, or the histology of biopsied focal liver lesions with a follow‐up period of at least six months. </p> <p>Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). </p> <p>CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-TST-001" target="_blank"><b></b></a></p> </div><img alt="MRI" data-id="CD014798-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-TST-001.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-TST-001.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>MRI</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references#CD014798-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014798-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/urn:x-wiley:14651858:media:CD014798:CD014798-TST-002" target="_blank"><b></b></a></p> </div><img alt="Secondary outcome" data-id="CD014798-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-TST-002.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_t/tCD014798-TST-002.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>Secondary outcome</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references#CD014798-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/media/CDSR/CD014798/image_n/nCD014798-TST-002.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014798-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of MRI for the diagnosis of HCC in people with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting:</b> clinical setting (secondary or tertiary care setting) or surveillance programmes </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design:</b> cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index test:</b> MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition:</b> HCC of any size, any stage </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b> </p> <p> <ul id="CD014798-list-0001"> <li> <p>Pathology of the explanted liver in case of transplantation</p> </li> <li> <p>Histology of resected focal liver lesion(s), or the histology of biopsied focal liver lesion(s) with a follow‐up of ≥ 6 months to exclude the presence of focal lesions not detected by the index test </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence: risk of bias and applicability concerns</b> </p> <p> <ul id="CD014798-list-0002"> <li> <p>Participant selection: high/unclear risk of bias 26 studies (76%); high concern for applicability 20 studies (59%) </p> </li> <li> <p>Index tests: high/unclear risk of bias 4 studies (12%); high concern for applicability 1 study (3%) </p> </li> <li> <p>Reference standard: high/unclear risk of bias 28 studies (82%); high concern for applicability 16 studies (47%) </p> </li> <li> <p>Flow and timing: high/unclear risk of bias 31 studies (91%)</p> </li> <li> <p>Overall: high risk of bias all included studies; high concern for applicability 29 studies (85%) </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Findings</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign=""> <p><b>Implications in a hypothetical cohort of 1000 people</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence</b><sup>a</sup><b>%</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True positives</b> will receive appropriate treatment (surgery or local ablative therapy or systemic chemotherapy) </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False negatives</b> will be misdiagnosed and not receive appropriate treatment </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True negatives</b> will not undergo inappropriate treatment or unnecessary further testing </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False positives</b> will undergo inappropriate treatment </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>34</p> <p>(4841)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>84.4% (80.1% to 87.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>93.8% (90.1% to 96.1%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>413</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>319</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HCC:</b> hepatocellular carcinoma; <b>MRI:</b> magnetic resonance imaging. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>We chose for exemplification three values of hepatocellular carcinoma prevalence: 36% for a population with low clinical suspicion, 56% as a median derived from our study analysis, and 66% for population with high clinical suspicion (assessment of nodules detected by ultrasound).<br/><sup>b</sup>Downgraded two levels for risk of bias and indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of hepatocellular carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014798-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of resectable hepatocellular carcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Review question:</b> what is the diagnostic accuracy of MRI for the diagnosis of resectable HCC in people with chronic liver disease? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Population:</b> adults with chronic liver disease </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Setting:</b> clinical setting (secondary or tertiary care setting) or surveillance programmes </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Study design:</b> cross‐sectional studies </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Index test:</b> MRI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Target condition:</b> resectable HCC </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Reference standards</b> </p> <p> <ul id="CD014798-list-0003"> <li> <p>Pathology of the explanted liver in case of transplantation</p> </li> <li> <p>Histology of resected focal liver lesion(s), or the histology of resected or biopsied focal liver lesion(s) with a follow‐up of ≥ 6 months to exclude the presence of focal lesions not detected by the index test </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>Limitations in the evidence: risk of bias and applicability concerns</b> (total 16 studies which had all participants with resectable HCC) </p> <p> <ul id="CD014798-list-0004"> <li> <p>Participant selection: high/unclear risk of bias 10 studies (63%); high concern for applicability 11 studies (69%) </p> </li> <li> <p>Index tests: high/unclear risk of bias 0 studies (0%); high concern for applicability 0 studies (0%) </p> </li> <li> <p>Reference standard: high/unclear risk of bias 10 studies (63%); high concern for applicability 11 studies (69%) </p> </li> <li> <p>Flow and timing: high/unclear risk of bias 14 studies (88%)</p> </li> <li> <p>Overall: high risk of bias; all included studies; high concern for applicability 11 studies (69%) </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Findings</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Implications in a hypothetical cohort of 1000 people</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prevalence</b><sup>a</sup><b>%</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True positives</b> will receive appropriate treatment (surgical resection) </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False negatives</b> will be misdiagnosed and not undergo surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>True negatives</b> will not undergo inappropriate further testing or surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>False positives</b> will undergo inappropriate further testing or surgical resection </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>MRI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16</p> <p>(2150)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>84.3% (77.6% to 89.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>92.9% (88.3% to 95.9%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>595</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>556</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>316</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HCC:</b> hepatocellular carcinoma; <b>MRI:</b> magnetic resonance imaging. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>We chose for exemplification three values of hepatocellular carcinoma prevalence: 36% for a population with low clinical suspicion, 56% as a median derived from our study analysis, and 66% for population with high clinical suspicion (assessment of nodules detected by ultrasound).<br/><sup>b</sup>Downgraded two levels for risk of bias and indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diagnostic accuracy of magnetic resonance imaging for the diagnosis of resectable hepatocellular carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014798-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post‐test probabilities</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Pre‐test</b> <b>probability</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Likelihood ratio</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Post‐test probability</b> </p> </th> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI positive</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5<sup>a</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>if MRI negative</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>MRI: magnetic resonance imaging</p> <p><sup>a</sup>Positive likelihood ratio.<br/><sup>b</sup>Negative likelihood ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post‐test probabilities</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014798-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for magnetic resonance imaging</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Analyses</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Specificity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (80.1 to 87.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8 (90.1 to 96.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Sensitivity analyses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary outcome (resectability 100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3 (77.6 to 89.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.9 (88.3 to 95.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positivity criteria clearly defined</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.9 (79.3 to 87.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8 (89.9 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reference standard blinded</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.8 (66.4 to 84.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.3 (81.5 to 94.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="24" valign="top"> <p><b>Subgroups analyses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Publication year</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published before 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.4 (72.8 to 89.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.3 (80.6 to 96.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.621</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Published after 2011</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.2 (80.2 to 89.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.6 (90.9 to 96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of cirrhosis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cirrhosis &gt; 90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.9 (78.7 to 88.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.3 (89.4 to 95.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.745</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cirrhosis &lt; 90%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.8 (80.1 to 93.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.8 (85.7 to 99.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Study location</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.9 (73.0 to 88.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (85.6 to 96.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.833</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>America</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.1 (82.5 to 90.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.4 (89.5 to 98.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (78.5 to 89.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.3 (83.7 to 96.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><i>Setting</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting clinical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (82.9 to 90.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.3 (88.1 to 96.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>0.243</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting confirmatory test after screening</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.1 (63.7 to 86.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.7 (75.1 to 97.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Setting initial screening test</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.0 (78.0 to 90.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.2 (92.2 to 98.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of resectable HCC</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &lt; 20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.7 (82.6 to 89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (70.4 to 95.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.593</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HCC resectable &gt; 20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.4 (79.5 to 89.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.6 (88.8 to 96.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><i>Reference standard</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.5 (62.8 to 88.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.2 (85.3 to 97.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>0.620</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.6 (83.7 to 92.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.4 (87.0 to 96.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OLT and histology</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.1 (76.1 to 83.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.9 (53.4 to 97.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mix</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.0 (77.8 to 91.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.2 (90.9 to 97.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Prevalence of viral aetiology</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral &lt; 80%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (83.8 to 90.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.5 (90.7 to 96.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral &gt; 80%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.9 (64.4 to 83.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5 (68.6 to 99.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>LI‐RADS positivity criteria</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LI‐RADS positivity criteria not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.4 (79.9 to 88.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (88.7 to 95.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.829</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LI‐RADS positivity criteria used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.7 (67.3 to 92.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.3 (88.2 to 98.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Type of contrast media</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gd extracellular + SPIO</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.2 (80.1 to 90.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.0 (87.7 to 96.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.793</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gd intracellular</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 (74.4 to 88.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.5 (88.0 to 98.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>Operator expertise</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Operator expertise reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (55.2 to 88.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.4 (85.3 to 98.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Operator expertise not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.2 (80.9 to 88.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.9 (89.8 to 96.4)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval; Gd: gadolinium; HCC: hepatocellular carcinoma; LI‐RADS: Liver Imaging Reporting and Data System criteria; OLT: orthotopic liver transplantation; SPIO: superparamagnetic iron oxide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Heterogeneity and sensitivity analyses for magnetic resonance imaging</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014798-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other systematic reviews on diagnostic accuracy of magnetic resonance imaging for hepatocellular carcinoma</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systematic</b> <b>review</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> <b>type</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of included studies</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants analysed</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Specificity (%)</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Use of bivariate statistical model</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0138" title="ColliA , FraquelliM , CasazzaG , MassironiS , ColucciA , ConteD , et al.Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. American Journal of Gastroenterology2006;101:513-23.">Colli 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6 (70 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.8 (77 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0131" title="ChenL , ZhangL , LiangM , BaoJ , ZhangJ , XiaY , et al.Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Academic Radiology2014;21(12):1603-13.">Chen 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (90 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (93 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (79 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (82 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (83 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (85 to 98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0128" title="ChanMV , HuoYR , TrieuN , MitchelleA , GeorgeJ , HeE , et al.Noncontrast MRI for hepatocellular carcinoma detection: a systematic review and meta-analysis – a potential surveillance tool?Clinical Gastroenterology and Hepatology2021;S1542-3565(21):00215-9.">Chan 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1685</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (83.9 to 89.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.3 (87.3 to 92.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (84 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (91 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0227" title="XieL , GuangY , DingH , CaiA , HuangY .Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound in Medicine and Biology2011;37(6):854-61.">Xie 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (82 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 (83 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="18" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0130" title="ChenL , ZhangL , BaoJ , ZhangJ , LiC , XiaY , et al.Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut2013;62:1520-1.">Chen 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (87 to 94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (93 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0167" title="JunqiangJ , YinzhongW , LiZ , ShulinG , XiaohuiW , YananZ , et al.Gadoxetic acid disodium (Gd-EOBDTA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. Journal of Magnetic Resonance Imaging2014;39(5):1079-87.">Junqiang 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>605</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (89 to 94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (93 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0181" title="LiuX , ZouL , LiuF , ZhouY , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One2013;8(8):e70896.">Liu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (89 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (94 to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0224" title="WuLM , XuJR , GuHY , HuaJ , ChenJ , ZhuJ , et al.Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?Digestive Diseases and Sciences2013;58(11):3313-25.">Wu 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (77 to 97)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (85 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0229" title="YeF , LiuJ , OuyangH .Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore)2015;94(32):e1157.">Ye 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>469</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (88 to 96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (94 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0135" title="ChouR , CuevasC , FuR , DevineB , WassonN , GinburgA , et al.Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Internal Medicine2015;162:697-711.">Chou 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83 (80 to 86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87 (79 to 93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0174" title="LeeYJ , LeeJM , LeeJS , LeeHY , ParkBH , KimYH , et al.Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology2015;275(1):97-109.">Lee 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 (74 to 83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0175" title="LiX , LiC , WangR , RenJ , YangJ , ZhangY .Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One2015;10(12):e0144247.">Li 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 (85 to 91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96 (94 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0176" title="LiYW , ChenZG , WangJC , ZhangZM .Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World Journal of Gastroenterology2015;21(14):4334-44.">Li 2015b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (82 to 88)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (73 to 83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0160" title="HannaRF , MiloushevVZ , TangA , FinklestoneLA , BrejtSZ , SandhuRS , et al.Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdominal Radiology2016;41(1):71-90.">Hanna 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.5 (73.1 to 79.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0158" title="GuoJ , SeoY , RenS , HongS , LeeD , KimS , et al.Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdominal Radiology2016;41(10):1960-72.">Guo 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86 (76 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (92 to 96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0169" title="KieransAS , KangSK , RosenkrantzAB .The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology2016;278(1):82-94.">Kierans 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1908</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (68 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (88 to 95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0182" title="LiuX , JiangH , ChenJ , ZhouY , HuangZ , SongB .Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transplantation2017;23(12):1505-18.">Liu 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1735</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92 (90 to 93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89 (87 to 91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0208" title="RobertsLR , SirlinCB , ZaiemF , AlmasriJ , ProkopLJ , HeimbachJK , et al.Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology2018;67(1):401-21.">Roberts 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82 (75 to 87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91 (82 to 95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0177" title="LiJ , WangJ , LeiL , YuanG , HeS .The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies. European Radiology2019;29(12):6519-28.">Li 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85 (77 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94 (88 to 97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0151" title="FengZ , ZhaoH , GuanS , WangW , RongP .Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: a systematic review and meta-analysis. Liver International2021;41(5):1117-28.">Feng 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 (69 to 78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93 (77 to 98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD014798-bbs2-0159" title="GuptaP , SoundararajanR , PatelA , KumarMP , SharmaV , KalraN .Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. Journal of Hepatology2021;75(1):108-19.">Gupta 2021</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per‐lesion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2807</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77 (74 to 81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimated</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Other systematic reviews on diagnostic accuracy of magnetic resonance imaging for hepatocellular carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/full#CD014798-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014798-tbl-0006"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 MRI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4841</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2150</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014798.pub2/references#CD014798-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014798.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014798-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014798-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014798-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014798-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD014798-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD014798-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD014798-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014798-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014798\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014798\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014798\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014798\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014798\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014798.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014798.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014798.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014798.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014798.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725104898"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014798.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725104902"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014798.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e73166d7a1be5',t:'MTc0MDcyNTEwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 